Gefitinib (ZD1839)

Catalog No.S1025

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Price Stock Quantity  
USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Gefitinib (ZD1839) Chemical Structure

Gefitinib (ZD1839) Chemical Structure
Molecular Weight: 446.90

Validation & Quality Control

Product Use Citation(85)

Customer Product Validation(11)

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Pan EGFR Inhibitor

    AZD8931 (Sapitinib) Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.

  • Most Potent EGFR Inhibitor

    Afatinib (BIBW2992) EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.
Targets Tyr1173 (NR6W cells) [1] Tyr1173 (NR6wtEGFR cells) [1] Tyr992 (NR6wtEGFR cells) [1] Tyr992 (NR6W cells) [1]
IC50 26 nM 37 nM 37 nM 57 nM
In vitro Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. [1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. [2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
KBNYO2O2hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Ttb2lEPTB;MD6wOVQh|ryPMmjlNVY2OTZ2N{O=
NIH3T3M3LmTWZ2dmO2aX;uJGF{e2G7Mny0NE4zKM7:TR?=M4T4b|IhcA>?NHHLbpdFVVORMmrxTY5pcWKrdHnvckBw\iCHR1[gd5RqdXWuYYTl[EBpfW2jbjDldoJDOSCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNESg{txOMX[xOlQ5ODJ6NB?=
COS7M3vsRmZ2dmO2aX;uJGF{e2G7NWXod2dtQTZizszNMm\hTY5pcWKrdHnvckBw\iCqdX3hckBLSUt{IG[2NVdHKG23dHHueEBmgHC{ZYPz[YQ>NXHkZ3YxOTdzN{i3NlI>
A549MXjDfZRwfG:6aXOgRZN{[Xl?NHTFdFY6PiCqNETTdZlFVVORNHLUUJRKSzVyPUGzMlU6KM7:TR?=MW[xPFMyOzhyNx?=
K562M4LIb2N6fG:2b4jpZ{BCe3OjeR?=MY[5OkBpNVi2NIE3TE2VTx?=MnTITWM2OD17LkO2JO69VQ>?NIfwco4yQDNzM{iwOy=>
MDA-MB-231Mn:2R5l1d3SxeHnjJGF{e2G7MUm5OkBpNHPBSpNFVVORMlLhTWM2OD1|Nj62NUDPxE1?NVnwUVFbOTh|MUO4NFc>
MOLT4MkXIR5l1d3SxeHnjJGF{e2G7NWDUc5k4QTZiaB?=MXHEUXNQNF3iTnhKSzVyPUG1MlAzKM7:TR?=NHLXZWwyQDNzM{iwOy=>
MCF7MknlR5l1d3SxeHnjJGF{e2G7M2rielUxKM7:TR?=MlXrO|IhcA>?NWGzTpNCUUN3ME2xNk4xPSEQvF2=MlrsNVg4PzF6MUm=
BT474MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFK1Noc4OiCqMXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKWNEe0JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKEWUQnKyJJdqfGhiRVO1NEBw\iByLkOg{txOMnfHNVkxOjh2MkS=
HN5NF:2ZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnm3O|IhcA>?MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiQNTDj[YxteyCxdnXy[ZhxemW|c3nu[{BGT0[UIIfpeIghTUN3MDDv[kAxNjBzIN88US=>NITYZnUyQTB{OESyOC=>
BA/F3NV\kUG5zS3m2b4TvfIlkKEG|c3H5MV23NkBpMXXDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEWJRmKgUFg2QFJibYX0ZY51KHerdHigTWM2OCCxZjCwMlAyODhizszNMXexPVI{QTJ{OR?=
NIH3T3MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvSSGpTPzJiaB?=M3X2eWdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJG5KUC9|VEOgZ4VtdHNiZYjwdoV{e2mwZzDldmIzKGenbnWge4l1cCCLQ{WwJI9nKDBwNUSg{txOM3HVcVE6PjZ3M{e3
MCF7 MXNGXKdFZHfW6ldHnvckBCe3OjeR?=NEK1Om0{OCCvaX6=M3LG[WlvcGmkaYTpc44hd2ZiQlPSVEBmgHC{ZYPz[YQhf2m2aDDJR|UxKG:oIEGuNUDPxE1?MUmxPVk{Ojl4MB?=
A431NFzsXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzZNVAh|ryPNYHKflcyPzJiaB?=M{L0TmdKPTB;MD61NVQh|ryPMkn6NVk6Pjl2NkW=
A431MnX1T4lv[XOnIFHzd4F6NYnGPIJ2OC5zIN88US=>M3ixT|EhcA>?M{DZWmlvcGmkaYTpc44hd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44>M4jv[VE6QTZ7NE[1
A431NUXzPW5oU2mwYYPlJGF{e2G7NEfFV20yODBizszNMkfhNVAhdWmwNVXhVnZNWHKxbH;u[4VlKGmwaHnibZRwenliYXP0bZZqfHlib3[gSWdHNWmwZIXj[YQhTUeIUjDwbI9{eGixconsZZRqd25?MWKxPVk3QTR4NR?=
Sf9M1TMXmtqdmG|ZTDBd5NigQ>?MkDyNVAhdWmwNEHYTGFFVVORMX3Jcohq[mm2aX;uJI9nKEWJRmKg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gdoVk\XC2b4KgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wN|Mh|ryPMmfONlAxPTZ2MkW=
NCI-H1975MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vPblUh|ryPNFL2bpk4OiCqMkD5TWM2OD16LkK2JO69VQ>?NFLQXWgzODF3MU[3NC=>
NCI-H1975Ml\rT4lv[XOnIFHzd4F6NELTZWMyOCEQvF2=NGfnepVKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?MUSyNFE2OTZ5MB?=
NCI-H1975NFvVfoFHfW6ldHnvckBCe3OjeR?=NF[xTGoyOCEQvF2=NGDO[olKdmirYnn0bY9vKG:oIFXSRmIzKGG3dH;wbI9{eGixconsZZRqd25?Mn\2NlAyPTF4N{C=
NCI-H1975NFHC[3RHfW6ldHnvckBCe3OjeR?=M3LvfVUh|ryPMUK0PEBpMX3JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGG|c3Xzd4VlKGG|IHHjeIl3[XSrb36gc4Yh[2G|cHHz[U0{NITicYwzODF3MU[3NC=>
A375M4GxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{n3NlQ5KGh?M4KwOmlEPTB;MkCuOVUh|ryPNVvwfpdTOjB|MES1N|c>
SMMC7721NG\5VGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLnOFghcA>?MWfJR|UxRTN|LkGyJO69VQ>?NFTkO4ozODNyNEWzOy=>
DU145MXvDfZRwfG:6aXOgRZN{[Xl?NFXwZ2k2KGR?MnHuSG1UVw>?NUPOSIV2UUN3ME20Nk4yPyEQvF2=NIHTeHUzODR4NkW1OS=>
MIAPaCa2NXL3[4p2S3m2b4TvfIlkKEG|c3H5MmPIOUBlNHfLT|VFVVORMon5TWM2OD13MD62NkDPxE1?NYTleYh3OjB2Nk[1OVU>
PANC1Mk\HR5l1d3SxeHnjJGF{e2G7MYG1JIQ>NWTlcIFJTE2VTx?=MlPQTWM2OD12MD60NkDPxE1?NUX4SXlzOjB2Nk[1OVU>
PC9NYe0V2IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFXHSnIu\GWoaXPp[Y51KGi3bXHuJHBEQSClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wNVch|ryPMmfWNlEzODh6MEK=
PC9MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjVfJJFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBoem:5dHitdoV{cXO2YX70JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO|aX7nJGVITlJiRUe0On9CPzVyL2S3PVBOKG23dHHueEB4cXSqIFXDOVAhd2ZiNzFOwG0>M2PuOVIyOjB6OECy
PC3NVPtcHhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jiXFExKM7:TR?=MXO3NkBpNULjcWpNTE2VTx?=MVHJR|UxRTdwNDFOwG0>M{f3W|IyOzV|NUS2
MDA-MB-468M2jJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfnfog3OTByIN88US=>MVm0PEBpMmDXSG1UVw>?M{[4UWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5NIjRXJIzOTR{OU[zNi=>
Plasmodium falciparumMo\1dWhVWyCycn;mbYxqdmdiZn;yJIlvcGmkaYTvdpMhd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJJBzd2yrZnXyZZRqd25?MXmyNVgyPzB2NR?=
NCI-H1993MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DzPVczKGh?MWfEUXNQNIW5V5pKSzVyPUCuNUDPxE1?MkH0NlE6OTZ2M{O=
NCI-H292M2PVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkD6O|IhcA>?NXH3epFuTE2VTx?=M1\V[WlEPTB;MD6wNkDPxE1?NYCwWpd[OjF7MU[0N|M>
A431Ml7MT4lv[XOnIFHzd4F6NWe4dHpXOiCqM1jFOmROW09?M1rSemlvcGmkaYTpc44hd2ZiRVfGVkBxcG:|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iQUSzNUB4cXSqIFnDOVAhd2ZiMD6wNFEh|ryPM3nJdlIzOTBzMUOy
MCF7MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4i1dlExOMLizsznM41NNGG2cGk1QCCqNV\0dnBzTE2VTx?=MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjDn[Y5mKHerdHigTWM2OCCxZjCxNk4xPSEQvF2=MYKyNlEyQTF|MB?=
BT474MmHDR5l1d3SxeHnjJGF{e2G7M4fhVVExKM7:TR?=MofKOFghcA>?M1;4Z2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KHOncoXtMZN1[XK4ZXSgbJVu[W5iQmS0O|Qh[2WubIO=NXnySXlxOjJzM{izNFg>
MCF7NX62dmM4S3m2b4TvfIlkKEG|c3H5MYWxNEDPxE1?MYK0PEBpMlSwR5l1d3SxeHnjbZR6KGGpYXnud5Qhe2W{dX2td5Rien[nZDDoeY1idiCPQ1[3JINmdGy|IH;2[ZIu\XiycnXzd4lv\yCHcnLCNkBk\Wyucx?=MUOyNlE{QDNyOB?=
HCC827M1XHWGtqdmG|ZTDBd5NigQ>?NYXxVVVWOC5zMkWg{txONY\jOnRsOjRiaB?=NXXvUpMyTE2VTx?=NWq3OYRmUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO|Q3NUF5NUCgcZV1[W62IGmxNFY5KGG3dH;wbI9{eGixconsZZRqd25?NEPne5YzOjN|OUO0Ni=>
HCC827M{f2W2tqdmG|ZTDBd5NigQ>?NH3JTHAxNjF{NTFOwG0>NEHxWlYzPCCqMXrEUXNQMXTJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQudWWmaXH0[YQhTXKtIIDoc5NxcG:{eXzheIlwdg>?MnTYNlI{Ozl|NEK=
HCC827NUjjNHp7U2mwYYPlJGF{e2G7NHjSOnIxNjF{NTFOwG0>NVLPeFdvOjRiaB?=MVHEUXNQMW\Jcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?M2eyblIzOzN7M{Sy
A431NWSz[2E5U2mwYYPlJGF{e2G7M3PXOlExOCEQvF2=MVWzNEBucW5?NYP2OnJWUW6qaXLpeIlwdiCxZjDFS2ZTKGSncnn2[YQh\nKxbTDoeY1idiCDNEOxJINmdGxibXXtZpJidmViYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyb3z5MWdtfS2WeYKgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAyNjB6IN88US=>M3[0XFIzPjl6N{iy
H460NHXWflJEgXSxdH;4bYMhSXO|YYm=NYe4TmRJPzJiaB?=MWnJR|UxRTVwNUmg{txONX7oOIUzOjJ5Mke0OFk>
HT-29MnXtR5l1d3SxeHnjJGF{e2G7NE\TTpk4OiCqM13KdGlEPTB;Mz6zOkDPxE1?MmOyNlI4Ojd2NEm=
SGC7901NV6yPVRkS3m2b4TvfIlkKEG|c3H5MkDvO|IhcA>?NHf1[W5KSzVyPUGwMlI3KM7:TR?=NWmzSll6OjJ5Mke0OFk>
A498MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\RRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNEm4JINmdGy|IHX4dJJme3OrbnegSWdHWiCjbnSgV3JEKHerdHigTWM2OCCxZjC4MlYh|ryPMVyyNlgyQDh2OB?=
Calu3MmjpR5l1d3SxeHnjJGF{e2G7Mnq0NVAh|rypL33MNYexR|R2PzJiaB?=NITkVotKSzVyPUGuOkDPxE1?NFnic4QzOzFzNkG2PC=>
FADUM2TYV2N6fG:2b4jpZ{BCe3OjeR?=MmXnNVAh|rypL33MMXe3NkBpNXjG[oY1UUN3ME2wMlA2KM7:TR?=NVjjbIJbOjNzMU[xOlg>
HCC827M2TSVGN6fG:2b4jpZ{BCe3OjeR?=MV6xNEDPxGdxbVy=NGLmOHc4OiCqMkHhTWM2OD1yLkCwNVUh|ryPMlvvNlMyOTZzNki=
PC9NELS[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXPeowyOCEQvHevcWw>M1\Y[|czKGh?MYLJR|UxRTBwMECxOEDPxE1?MViyN|EyPjF4OB?=
Sf9NELtPYlMcW6jc3WgRZN{[Xl?NUHKZ4pkOSCqMmjvSG1UVw>?MlP2TY5pcWKrdHnvckBw\iCqdX3hckBIW1RvdHHn[4VlKEWJRmKgUFg{PFJibYX0ZY51KGW6cILld5Nm\CC5aYToJGlEPTBib3[gNE4xOTVizszNNFexbnMzOzZzMU[5NS=>
16HBE14o-NVnEOpY3S3m2b4TvfIlkKEG|c3H5NYG2Rld5OTBizszNMWG3NkBpM{\BZmROW09?M{LUUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFE3UEKHMUTvMUBk\WyuczDoZZJjd3Krbnege4lt\CC2eYDlJGVITlJiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDF{LkexJO69VQ>?MXKyN|Y3QDR2MR?=
NCI-H1975NGP5dlZEgXSxdH;4bYMhSXO|YYm=NGjJXXoyOCEQvF2=NW\3RmpzPzJiaB?=MXnEUXNQNGTkeIdEgXSxdH;4bYNqfHliYXfhbY5{fCCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKE6FST3INVk4PSClZXzsd{Bp[XKkb4LpcochTUeIUjDMPFU5Wi:WN{mwUUBld3WkbHWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB4LkmxO{DPxE1?M1jt[lI{PjZ6NESx
16HBEMkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTHO|IhcA>?MnSySG1UVw>?M4rlZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iMU\IRmUh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhTUeIUjD3bZRpKEmFNUCgc4YhOS54MEGg{txOM3q0OVI{Pzl{M{G4
16HBENH;yeYJHfW6ldHnvckBCe3OjeR?=MlnzNVAxKM7:TR?=Mo\zNVUxKG2rbh?=NEjCPHNFVVORM1fxPGlv\HWldHnvckBw\iCwaYTybYMhd3irZHWgdJJw\HWldHnvckBqdiCqdX3hckAyPkiERTDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDFS2ZTMorPNlM4QTJ|MUi=
A549NWLieYFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWm3NkBpMXfEUXNQMYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIfpcIQhfHmyZTDFS2ZTN2tvUnHzJIRmeGWwZHXueEBpfW2jbjDBOVQ6KGOnbHzzJJdqfGhiSVO1NEBw\iB2Lk[yOkDPxE1?M3PoelI{Pzl{M{G4
SH-SY5YM3LQPWN6fG:2b4jpZ{BCe3OjeR?=MYC3NkBpMmHJTWM2OD1zOD6yNUDPxE1?M33MdFI{QDdzOUC5
LoVoMUnLbY5ie2ViQYPzZZk>NULnTlNSOiBiaB?=MonYSG1UVw>?NVrrVWdGUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wOlIh|ryPMYiyN|k{ODl7NB?=
PC9MUjLbY5ie2ViQYPzZZk>MoLrNkBpNYHxSpJDTE2VTx?=M1vlWWlvcGmkaYTpc44hd2ZiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJIFkfGm4YYTpcochdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR|kh[2WubIOge4l1cCCLQ{WwJI9nKDBwMEC4O{DPxE1?NYDa[mVIOjN7M{C5PVQ>
HCC827NXPmfmFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYC3NkBpM4H0fGlEPTB;MD6wNVIh|ryPNWmwS2JlOjN7N{OxOlg>
A549MnPnT4lv[XOnIFHzd4F6NFnCT5oyKM7:TR?=NITaR3MyKGh?NWTTUohLTE2VTx?=MYjJcohq[mm2aX;uJI9nKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wN|k6KM7:TR?=MVWyN|k5QDN3NB?=
A549NY\DSVV5TnWwY4Tpc44hSXO|YYm=NVu4W5RYOSEQvF2=MoryNUBpNFnWRZZFVVORMW\D[YxtfWyjcjD1dJRic2V?NUPJVop{OjN7OEizOVQ>
HCC827NVnkWlFDU2mwYYPlJGF{e2G7NXXUeGJ5OC53IN88US=>NFXYXGUzKGh?NUjZfYxCTE2VTx?=M1rWcWlvcGmkaYTpc44hd2ZiRVfGVkBxcG:|cHjvdplt[XSrb36gbY4h\2WoaYTpcoljNXKnc3nzeIFvfCCqdX3hckBJS0N6MkegZ4VtdHN?NHrwPXEzOzl7M{OyPC=>
HCC827NXPwZWNsTnWwY4Tpc44hSXO|YYm=MXOwMlUh|ryPM{TwS|IhcA>?MmiySG1UVw>?NEfZR3ZKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\Wyucx?=NIqwW4MzOzl7M{OyPC=>
HCC827MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7yNVAh|ryPNHXoSpM4OiCqM1fXSWROW09?NE\sOY5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIdm\mm2aX7pZk1{\W6|aYTpeoUhcHWvYX6gTGNEQDJ5IHPlcIx{KGijcnLvdolv\yCHR1\SJGU4PDZidH:gRVc2OCCmZXzleIlwdiC5aYToJGlEPTBib3[gNE4xODV6MTFOwG0>M4HOUVI1ODV|Nke0
A431NUS1VVNsU2mwYYPlJGF{e2G7Mni2NVAxKM7:TR?=MYKzNEBucW5?M2DYVGlvcGmkaYTpc44hd2ZiRVfGVkBqdiC|aHXkJI1mdWK{YX7lJJZme2mlbHXzJJdqfGhiSVO1NEBw\iBzLkGg{txONHL4cFIzPDB7NESzNi=>
BCRP-MDCK2M1uzW2Z2dmO2aX;uJGF{e2G7MXGxMlgh|ryPMVG3NkBpNH7LRlhFVVORNITYbZNKdmO{ZXHz[UBw\iCybHHzcYEhdWWvYoLhcoUh\XiycnXzd4lwdiCxZjDCR3JRKGW6cILld5NqdmdicnXwc5J1\XJiZ3Xu[UBITlB?M4\OSFI1OTh2MkGz
BCRP-MDCK2NX\xbpFLTnWwY4Tpc44hSXO|YYm=NULBfIRnOS56IN88US=>MVi3NkBpMlXrSG1UVw>?NUHkXFA2WmWmdXP0bY9vKG:oIIDsZZNu[SCvZX3idoFv\SCneIDy[ZN{cW:wIH;mJGJEWlBiZYjwdoV{e2mwZzDy[ZBwenSncjDn[Y5mKEeIUB?=MlzCNlQyQDR{MUO=
MDCKMY\DfZRwfG:6aXOgRZN{[Xl?NX\ibGM6PzJiaB?=NX7S[I5ZTE2VTx?=M2GzW2dKPTB;MT60OUDPxE1?MWKyOFE5PDJzMx?=
MDCK2Mni4SpVv[3Srb36gRZN{[Xl?MoDaNU45KM7:TR?=M2DYNlczKGh?NVzCOmxDTE2VTx?=Mn:zTY5pcWKrdHnvckBw\iCqdX3hckBDS1KSIHX4dJJme3OnZDDhd5Nme3OnZDDhd{BJd2WlaIP0JFM{OzR{IHHjZ5VufWyjdHnvckB4cXSqIFnDOVAhd2ZiMz6xPUDPxE1?NF:wV4ozPDF6NEKxNy=>
A431MWPDfZRwfG:6aXOgRZN{[Xl?MkDtO|IhcA>?MkDhSG1UVw>?M4LGTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh\XiycnXzd4lv\yCHR1\SJJdqfGhiSVO1NEBw\iByLkW1JO69VQ>?MW[yOFQyOTF{Mx?=
Calu3NV\uW2tbS3m2b4TvfIlkKEG|c3H5MX[3NkBpNGTLPIhFVVORMVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDZYx2OyClZXzsd{BmgHC{ZYPzbY5oKEiHUkKge4l1cCCLQ{WwJI9nKDBwOUmg{txOMXWyOFQyOTF{Mx?=
KBMojET4lv[XOnIFHzd4F6MkLQNVAh|ryPNX\x[GVzOSCqNXjENVRVTE2VTx?=MmTETY5pcWKrdHnvckBw\iCHR1[td5RqdXWuYYTl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIFXHSnIhf2m2aDDJR|UxKG:oIECuNFI2KM7:TR?=M1;GcVI1PDFzMUKz
BEAS2BNXH1TFFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfGUYI2OCEQvF2=Mmn2O|IhcA>?NGLwZ45FVVORMVHJR|UxRTF|Lkm0JO69VQ>?NGLCcYMzPDZyN{W5NS=>
NCI-H1975M3r5R2Z2dmO2aX;uJGF{e2G7M4jNVlExOCEQvF2=M3WzUFE2OCCvaX6=MkfNSG1UVw>?NF\1fYRKdmS3Y4Tpc44hd2ZiTl:gdJJw\HWldHnvckBqdiCqdX3hckBPS0lvSEG5O|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2gcZV1[W62M{LkTFI1PjB5NUmx
HelaMnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlW2NlQhcA>?MWHEUXNQM3q4NmlEPTB;Mj62O{DPxE1?NHL6dWozPDd|MUK4NS=>
HepG2M1G5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzHbYFWOjRiaB?=NFjheWdFVVORNXzZ[2lXUUN3ME22MlQzKM7:TR?=MXWyOFc{OTJ6MR?=
Sf9NWrpWWs2U2mwYYPlJGF{e2G7MY[xNEBucW5?MX3EUXNQNIXKV|lKdmirYnn0bY9vKG:oIHH1eI9xcG:|cHjvdplt[XSrb36gc4YhemWlb33ibY5idnRiaHnzMZRi\2enZDDFS2ZTKCijbXnuc{Bi[2mmIE[0OU0yOTh4KTDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMEKg{txONGq4T2IzPDd|MUK4NS=>
SW620M4XQUmN6fG:2b4jpZ{BCe3OjeR?=NXvYdGZGPDhiaB?=MXrEUXNQMYHJR|UxRTJ6LkKg{txOM3rQVVI1QTByNUm0
HCC827NE\UUWJHfW6ldHnvckBCe3OjeR?=MkXYNE42KM7:TR?=NXm3cHg6OiCqNWPhT3g{TE2VTx?=MVfkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdg>?M1TwV|I{QTl|M{K4
HCC827NEXPR5pHfW6ldHnvckBCe3OjeR?=MV2wMlUh|ryPNYHG[|FTOiCqMVHEUXNQMWHkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YheDR2L{SyJJBpd3OyaH;yfYxifGmxbh?=NEKwVnczOzl7M{OyPC=>
HCC827NHf5WG1EgXSxdH;4bYMhSXO|YYm=MoHGNE42KM7:TR?=MnO2O|IhcA>?NGfneo5FVVORMWjoZZMhdm9iY4n0c5RwgGmlaYT5M4L6WlI{QTl|M{K4
NCI-H1975NECw[mVHfW6ldHnvckBCe3OjeR?=NXjPXIF2OTBizszNM{i2cVghcA>?M3HiSmROW09?M4HpOIRw\XNibn;0JIlvcGmkaYTpJGVITlJiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUSzDwbI9{eGixconsZZRqd25?NV7hZnZyOjNzMU[xOlg>
A431MnrPT4lv[XOnIFHzd4F6M3Pmc|Eh|ryPMXWxJIg>NXvpdYloTE2VTx?=MmDvbIF{KG6xIHnydoV3\XK|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?MY[yOFkxODV7NB?=
LNCaPNFPK[5dHfW6ldHnvckBCe3OjeR?=NXrMUIM5OTBizszNMVKybEBweiB2IHi=M3z6d2ROW09?NGfwWnlld2W|IH7veEBqdmirYnn0JIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiaX3teY5weHW{aX\p[YQh\myjZz30ZYdo\WRiQn34JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzN{UG3BWHA>MXexPFY3PzNzMh?=
H1975MUPLbY5ie2ViQYPzZZk>NIrhc3IyKM7:TR?=MV:yOEBpNWS2UHRNTE2VTx?=NVf2T2lK\G:nczDuc5QhcW6qaXLpeEBGT0[UIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCKMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?NUW0W3Q4OjR4MEe1PVE>
H1975NW\YfHdyTnWwY4Tpc44hSXO|YYm=NUHhfodnOSEQvF2=MXuyOEBpMkixSG1UVw>?MUnkc4V{KG6xdDDpcohq[mm2IFXST{BxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0>MlrFNlQ3ODd3OUG=
HCC827M4Xh[WtqdmG|ZTDBd5NigQ>?M13EdFAvOTFizszNM1\JNVEhcA>?M1PScGROW09?MWXoZZMhdm9iaYLy[ZZmenOrYnzlJIlvcGmkaYTpc44hd2ZiRVfGVkBie3Onc4Pl[EBieyC{ZXPveoVzgSCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?MVqyOFEzPDh7OB?=
H1975Mo\TT4lv[XOnIFHzd4F6NHXCT|gxNjN|IN88US=>MYWyJIg>NVGybFM{TE2VTx?=NHewOVlld2W|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hSUuWIIDoc5NxcG:{eXzheIlwdg>?MnGwNlQyOjR6OUi=
H1975Mln5T4lv[XOnIFHzd4F6Moe4NE4{OyEQvF2=MYKyJIg>M4LjZ2ROW09?MnvO[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGVTUyCyaH;zdIhwenmuYYTpc44>MXGyOFEzPDh7OB?=
H1975MmnYT4lv[XOnIFHzd4F6NH\hb|QxNjN|IN88US=>NWHr[mw6OiCqNGTlUYdFVVORMUjkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:|cHjvdplt[XSrb36=NFfzfZEzPDF{NEi5PC=>
H1975MkfaT4lv[XOnIFHzd4F6NFrwRXcxNjF{NTFOwG0>M1PYOVI1KGh?NGL1Z3FFVVORNHXSXVdld2W|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62IGmxNFY5KGG3dH;wbI9{eGixconsZZRqd25?NG\pWoUzOjN|OUO0Ni=>
H1975NUWxfnlTU2mwYYPlJGF{e2G7MUewMlUh|ryPMkfzNlQhcA>?NVzvNJNHTE2VTx?=M{HwO4Rw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRvbXXkbYF1\WRiRYLrJJBpd3OyaH;yfYxifGmxbh?=MYCyNlM{QTN2Mh?=
H1975M3HKeGtqdmG|ZTDBd5NigQ>?NWjpdoJGOC53IN88US=>NF7JOmMzPCCqMm\mSG1UVw>?NG\NfJZld2W|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62LX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36=NH\hdmUzOjN|OUO0Ni=>
MIAPaCa2MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLmNk42KM7:TR?=MoK4O|IhcA>?MofLSG1UVw>?M1T6[ohieyCwbzDndo94fGhiaX7obYJqfGmxbh?=M1zZRVIxPDZ4NUW1
MIAPaCa2NGe4VIxEgXSxdH;4bYMhSXO|YYm=MUGxJO69VQ>?NYOyc|U4OTBiZB?=MXnEUXNQM2\GTIhieyCwbzDjfZRwfG:6aXPpeJkh[XO|ZYPz[YQh[XNic4XwdJJme3Orb36gc4Yh[2:ub375JIZwem2jdHnvci=>MXyyNFQ3PjV3NR?=
MIAPaCa2MWjBdI9xfG:|aYOgRZN{[Xl?MYOxNEDPxE1?NYezboVqOjSqIH;yJFQ5KGh?NW[4[nprTE2VTx?=MV3kc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|NYHiU5N1OjB2Nk[1OVU>
MIAPaCa2MlfzRZBweHSxc3nzJGF{e2G7M2jVc|IxKM7:TR?=M1rFbFI1KGh?M3XlSGROW09?Mlns[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk[XOyYYPlJFMh[WO2aY\heIlwdg>?NV7QSnA{OjB2Nk[1OVU>
EoL-1NVH3OldOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfpRYV[UUN3ME21MlE4KG6PMk\OV2FPT0WU
NCI-H720NVrkRWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIC5XmhKSzVyPUK2MlkzKG6PM2PtbHNCVkeHUh?=
NCI-SNU-5MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVqzTIVUUUN3ME2yPE4yQSCwTR?=NXf3OJVbW0GQR1XS
EW-3NUnubGtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfVTWM2OD12Nj6wOEBvVQ>?NFXi[IVUSU6JRWK=
HCC2218M1fhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTHPZdZUUN3ME21NE42QSCwTR?=M1TKbXNCVkeHUh?=
HuO-3N1Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLwTWM2OD13Nj6wPUBvVQ>?NIDVUpNUSU6JRWK=
DBMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYqyZYNZUUN3ME22NE46PiCwTR?=NWrKbFdFW0GQR1XS
HSC-4MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPQSpYzUUN3ME22NU42OyCwTR?=NHfHToJUSU6JRWK=
DOKNFTjcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzwR3RFUUN3ME25N{43OiCwTR?=MWPTRW5ITVJ?
H9M1vPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4[yVWlEPTB;MUO3MlIhdk1?MlLYV2FPT0WU
NCI-H292NIHkWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTF4Mj62OkBvVQ>?NILyeoRUSU6JRWK=
HSC-2NHvSR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTF4NT61O{BvVQ>?M4\UWHNCVkeHUh?=
LU-65MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTF4Nj62NUBvVQ>?MYLTRW5ITVJ?
BV-173MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;Zc21sUUN3ME2xPFYvPTVibl2=MUDTRW5ITVJ?
LB2241-RCCNX3q[o42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LC[GlEPTB;MUm0Mlk{KG6PMoS4V2FPT0WU
KG-1NVPuVWhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTJyND6zOEBvVQ>?MVjTRW5ITVJ?
CHL-1NFn3fFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXVOmpoUUN3ME2yNFgvPTFibl2=MYPTRW5ITVJ?
KYSE-140MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojsTWM2OD1{MEmuPVYhdk1?NXvNbG1zW0GQR1XS
DU-145NYTDWXRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rhV2lEPTB;MkG5MlA1KG6PMn35V2FPT0WU
EW-13NEjOPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUH1NpVqUUN3ME2yNlUvOSCwTR?=NGXQR4JUSU6JRWK=
KYSE-450Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLvdWJ4UUN3ME2yOFcvQTJibl2=MnS0V2FPT0WU
CAL-72NYPPNGdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTQV2dKSzVyPUK2PE44OyCwTR?=NU\vRoRFW0GQR1XS
MEG-01MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTJ5Nj63OkBvVQ>?NH:3NG1USU6JRWK=
HCE-TM4PBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTJ5OT63PUBvVQ>?NGLPdmtUSU6JRWK=
NCI-SNU-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PJV2lEPTB;MkizMlMzKG6PMVjTRW5ITVJ?
CAL-27NYTxe2p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHznN4lKSzVyPUK4PU4xQCCwTR?=MX7TRW5ITVJ?
BALL-1NWPYVYNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIf1OHRKSzVyPUK5O{41OiCwTR?=NFfiZWxUSU6JRWK=
SBC-1NXLSZWxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXPenc2UUN3ME2zNFcvPzlibl2=NEHnT3RUSU6JRWK=
CAL-54NHfwT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{m1WWlEPTB;M{GxMlI{KG6PNWC4[IVyW0GQR1XS
TI-73MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDiTWM2OD1|MUKuO|Uhdk1?M4jEb3NCVkeHUh?=
P12-ICHIKAWAM{m2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTN{OD6wOkBvVQ>?MYnTRW5ITVJ?
ACHNMlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInDVXpKSzVyPUOzNU41KG6PNF7JOYZUSU6JRWK=
PC-14MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTN|Mz60NUBvVQ>?NEi1TVhUSU6JRWK=
HCC1806NGrOUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknkTWM2OD1|M{euOVEhdk1?NX7ab2Q3W0GQR1XS
SK-MEL-24NUTOdWxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\INWZQUUN3ME2zN|cvQDdibl2=NHTyeZlUSU6JRWK=
A4-FukM1S3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3TTZRXUUN3ME2zOVAvODJibl2=NWmwdmRZW0GQR1XS
ECC10NVX5OZdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrjW3pKSzVyPUO1Nk46PiCwTR?=MVLTRW5ITVJ?
KASUMI-1NF;ZdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7qXYlYUUN3ME2zOlYvPzNibl2=NHO5dWJUSU6JRWK=
CAL-33NV\CcoFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTN5MD65JI5ONGThbpRUSU6JRWK=
MDA-MB-175-VIINYWyNmxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHWTWM2OD1|N{iuPFghdk1?M4PESnNCVkeHUh?=
NUGC-3NX\v[oxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{H6VmlEPTB;NECxMlgyKG6PM4e4dnNCVkeHUh?=
KY821MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LyPGlEPTB;NEC4MlU4KG6PMUXTRW5ITVJ?
CTB-1M4rCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXrTWM2OD12MkSuOEBvVQ>?NXzwZnlvW0GQR1XS
DoTc2-4510NEnNeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYS5V4V4UUN3ME20OFIvOTJibl2=NVrPWmtKW0GQR1XS
EFO-27Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4O2SmlEPTB;NEW0Mlc1KG6PM{m3R3NCVkeHUh?=
BPH-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWO5e2k2UUN3ME20PVEvOTZibl2=MofaV2FPT0WU
KYSE-270NH7OXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjxW4FtUUN3ME20PVgvPjVibl2=M4jMT3NCVkeHUh?=
HO-1-N-1Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3VNGZKSzVyPUWwPU4zPSCwTR?=M1ixenNCVkeHUh?=
SK-MEL-1MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDDcG5wUUN3ME21NVAvQTlibl2=MWXTRW5ITVJ?
MOLT-13M4H0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTVzND64NkBvVQ>?M2fBSnNCVkeHUh?=
TK10NGC4eodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTVzNT6xNUBvVQ>?NH;4XZhUSU6JRWK=
HNNUnVWHF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrhboNKSzVyPUWxO{4{QCCwTR?=NGXvellUSU6JRWK=
SCC-15Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3ewRmlEPTB;NUK1MlY5KG6PM1nGUXNCVkeHUh?=
NCI-H358NWDTO|ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTV{Nz62OkBvVQ>?M4fVOHNCVkeHUh?=
KYSE-180NGq5TmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\ic2lEPTB;NUOwMlYzKG6PNWraVpc5W0GQR1XS
NCI-H82MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTV2MD61JI5OM3\3UXNCVkeHUh?=
NB7MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHlR5RXUUN3ME21OFYvOzJibl2=Mlm3V2FPT0WU
DSH1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3MfHF1UUN3ME21OlYvQDhibl2=MkX4V2FPT0WU
RS4-11NXz3OplRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVi2bWlDUUN3ME21OlgvPTlibl2=M161SHNCVkeHUh?=
CANMmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Moj4TWM2OD13OECuO|Yhdk1?NYXidIpVW0GQR1XS
Ca9-22NUTlRZFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTV6OD62OEBvVQ>?M4X1eXNCVkeHUh?=
CAL-39M3PSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTV7Nj6zJI5OMX7TRW5ITVJ?
NCI-H1623NETJVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;rT2lEPTB;NUm5MlM3KG6PMlv3V2FPT0WU
FADUNEjMPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGi2OnZKSzVyPU[wOE43QSCwTR?=M1TjfHNCVkeHUh?=
NB69M4rWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NICzUZlKSzVyPU[xOE4{PSCwTR?=NX;MOnhlW0GQR1XS
Ramos-2G6-4C10M1HwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnYbVlQUUN3ME22NlEvPDZibl2=MVzTRW5ITVJ?
LB1047-RCCM{fLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnLTWM2OD14MkWuNlkhdk1?MmnwV2FPT0WU
MV-4-11MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFG4[WtKSzVyPU[yO{44KG6PMVXTRW5ITVJ?
DBTRG-05MGNGX1bY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILr[phKSzVyPU[zNk4zQCCwTR?=M{j2RXNCVkeHUh?=
ME-180NH;TfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PyeGlEPTB;NkOyMlkhdk1?NX;mPIR2W0GQR1XS
NBsusSRMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTZ2Nj61NkBvVQ>?MWLTRW5ITVJ?
COR-L105NXn3TmVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTZ4Mj61N{BvVQ>?NVfDVHptW0GQR1XS
ETK-1MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF62V5hKSzVyPU[2Nk42QSCwTR?=MnK4V2FPT0WU
L-363MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIq0bXFKSzVyPU[3NU46PCCwTR?=NFTzN5BUSU6JRWK=
LU-134-ANFX1Z21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLxNWpMUUN3ME23NVkvODlibl2=M17EbXNCVkeHUh?=
NCI-H1770MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\2R|RIUUN3ME23NlIvPCCwTR?=NHrrTmFUSU6JRWK=
HAL-01NF\ZcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnRTWM2OD15M{SuO|Ehdk1?NWLyUYE3W0GQR1XS
COLO-684NHvWcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Ts[mlEPTB;N{WzMlAyKG6PMoPyV2FPT0WU
TE-6NUjFNHdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XmZ2lEPTB;N{[0MlMyKG6PNH:zXnRUSU6JRWK=
A431MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnRXlF{UUN3ME23PFAvODRibl2=Mn:wV2FPT0WU
LU-135NInJfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPQTWM2OD15OEOuNFMhdk1?NFjZSoJUSU6JRWK=
EC-GI-10MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nLWGlEPTB;N{i4MlUzKG6PMUHTRW5ITVJ?
TE-12NXrWR|c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHzUGhJUUN3ME24NlEvOTFibl2=NILqN2xUSU6JRWK=
LoVoMkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXYSWtKSzVyPUi1PU4xPiCwTR?=MlHoV2FPT0WU
23132-87Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTNRoRXUUN3ME24OlQvOjhibl2=NEHwWJNUSU6JRWK=
AU565NYrmW|N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvL[VVYUUN3ME24OlkvPiCwTR?=NEX1[|RUSU6JRWK=
DELM3TGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfweY9SUUN3ME24O|cvPjVibl2=MmnrV2FPT0WU
COR-L88NGnl[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITzPJhKSzVyPUi4Nk4zPiCwTR?=NV7k[YpGW0GQR1XS
NCI-H2126MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTh6Mj64N{BvVQ>?MnXRV2FPT0WU
CAPAN-1NV;Qb3lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH23XFhKSzVyPUi4N{4zQSCwTR?=MXHTRW5ITVJ?
BT-474NFXuZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTl|OD6xOEBvVQ>?NITMUGtUSU6JRWK=
BHYNUnvPGU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HIeGlEPTB;OUe1MlQ5KG6PMmCyV2FPT0WU
HT-3NEPuW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzKR29KSzVyPUm4Nk41OSCwTR?=MlGyV2FPT0WU
SK-NEP-1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTl6OT60OEBvVQ>?M1X6[XNCVkeHUh?=
MS-1NFPjd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnsdJVKSzVyPUm5OE43QSCwTR?=MmTGV2FPT0WU
DOHH-2NF3jW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTFwMECwNlEh|ryPMmC1V2FPT0WU
NCI-H1304M1L5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vaXmlEPTB;MT6wNVY1OyEQvF2=NFTXVHJUSU6JRWK=
EM-2NVLnV41YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTOTWM2OD1zLkCzNFE3KM7:TR?=NIfOZllUSU6JRWK=
MHH-PREB-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF[3WJhKSzVyPUGuNFg1PTFizszNM3zzZ3NCVkeHUh?=
KU-19-19MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTJTWM2OD1zLkC4OVQyKM7:TR?=MXnTRW5ITVJ?
NCI-H1648MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7TU2dYUUN3ME2xMlExPjF4IN88US=>NFzPTJFUSU6JRWK=
MKN1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTpT4JKSzVyPUGuNlE6QDdizszNNGjjb5NUSU6JRWK=
SNU-449MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrVT2dqUUN3ME2xMlIzOjB6IN88US=>MWjTRW5ITVJ?
OAW-42MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjnVW9YUUN3ME2xMlI4QDJ3IN88US=>MonVV2FPT0WU
769-PM3vEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3u3fWlEPTB;MT6yO|kyQCEQvF2=MYrTRW5ITVJ?
SW1088MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHHTWM2OD1zLkK5OlA4KM7:TR?=MoXNV2FPT0WU
GCIYNInHNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDzTWM2OD1zLkOwNVMzKM7:TR?=M13qVXNCVkeHUh?=
CTV-1NH;6NGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU[w[4xCUUN3ME2xMlMxQCEQvF2=MXHTRW5ITVJ?
NCI-H1092M4\vWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPXV4N2UUN3ME2xMlMxQDVizszNNIHHdoZUSU6JRWK=
NKM-1MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjibGpZUUN3ME2xMlMzPTl5IN88US=>M{S0T3NCVkeHUh?=
NCI-H1650MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXPTWM2OD1zLkOzOFgzKM7:TR?=NV6yW3FOW0GQR1XS
SW954MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfLfpZKSzVyPUGuN|QxPDhizszNNXm1dWFPW0GQR1XS
SW48Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTFwM{[2NVgh|ryPNV:1V2d7W0GQR1XS
SK-N-DZNGP0dnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1L6cGlEPTB;MT6zOlk1PyEQvF2=M4XDe3NCVkeHUh?=
KMOE-2NFeyNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTFwM{m4NVUh|ryPMULTRW5ITVJ?
NB5MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTrXIlFUUN3ME2xMlQxQDl2IN88US=>NUHlclRMW0GQR1XS
CCRF-CEMMnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfpTWM2OD1zLkSxNVEh|ryPNVLOWYZLW0GQR1XS
RH-1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTFwNEGxN|Yh|ryPNYjMU4F6W0GQR1XS
NCI-H526MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;XTY5SUUN3ME2xMlQ{QDJ4IN88US=>MX\TRW5ITVJ?
697NXPqToR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHGzOXVKSzVyPUGuOFQyODRizszNNW\icYdwW0GQR1XS
J82M3\W[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;LTWM2OD1zLkS1O|Y3KM7:TR?=NXLaNndHW0GQR1XS
BE-13NGfsVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYj4dFlJUUN3ME2xMlUxPjdzIN88US=>MVHTRW5ITVJ?
SASNETrRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\qWohkUUN3ME2xMlUyPjJ{IN88US=>NHv6VZdUSU6JRWK=
SCC-25NEDzSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTFwNUKzNlIh|ryPNX;BZZl6W0GQR1XS
LAMA-84M1HOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrxTWM2OD1zLkWzPFE2KM7:TR?=M3LxbXNCVkeHUh?=
HSC-3NF63eFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETK[VVKSzVyPUGuOVQ{QCEQvF2=M2fXTHNCVkeHUh?=
BT-549MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfjTWM2OD1zLkW4O|Q4KM7:TR?=NVXNUpNPW0GQR1XS
ML-2NWK0bWVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTTTWM2OD1zLk[0NFI6KM7:TR?=MUTTRW5ITVJ?
BB30-HNCMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzw[WVKSzVyPUGuOlg6PzJizszNMVXTRW5ITVJ?
PANC-03-27NELGR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVG1UlNNUUN3ME2xMlcxOTN7IN88US=>MWTTRW5ITVJ?
COLO-678NHq2PVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvrdpYyUUN3ME2xMlc{PDR2IN88US=>M3PZbHNCVkeHUh?=
NCI-H1666NUfMZlhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fLd2lEPTB;MT63OFcxPCEQvF2=M2fKfnNCVkeHUh?=
NCI-H209MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFm3eHlKSzVyPUGuO|czPjlizszNNYXyNm1LW0GQR1XS
EPLC-272HMlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHOe5hYUUN3ME2xMlg2PTR7IN88US=>NFPzWndUSU6JRWK=
OMC-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LxPWlEPTB;MT65PVg5QCEQvF2=MUTTRW5ITVJ?
HCC70NULidG1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jpb2lEPTB;Mj6wNFgyPSEQvF2=MXnTRW5ITVJ?
CAL-12TNG[wcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvXTWM2OD1{LkCxPFYyKM7:TR?=M{mzSnNCVkeHUh?=
TGBC24TKBNITuV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTJwMEK5OlEh|ryPMX\TRW5ITVJ?
EKVXM2PrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PaXWlEPTB;Mj6wOFk{QSEQvF2=NYKzc4x6W0GQR1XS
SW1116MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXCTWM2OD1{LkC2NFA6KM7:TR?=NHnuepVUSU6JRWK=
NCI-H2009NVrDVotKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nCd2lEPTB;Mj6wOlIyPCEQvF2=NIXxXo5USU6JRWK=
RPMI-8866MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3G1SGlEPTB;Mj6wPFQ5OSEQvF2=M3HjU3NCVkeHUh?=
KARPAS-45M3XLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\I[mR3UUN3ME2yMlEzPDd7IN88US=>NX3HeJNCW0GQR1XS
RXF393M1;RNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDIVFF6UUN3ME2yMlE{ODN4IN88US=>NIDJXFBUSU6JRWK=
786-0MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmG1TWM2OD1{LkG4OFA3KM7:TR?=M{LYc3NCVkeHUh?=
SCC-4MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfucW4{UUN3ME2yMlIyPzd4IN88US=>NEXuSGlUSU6JRWK=
BT-20MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHS[mhKSzVyPUKuNlY4PDRizszNM3nsZ3NCVkeHUh?=
A498M3Tvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLxTWM2OD1{LkK5OFE2KM7:TR?=NUfzfHlMW0GQR1XS
IGROV-1M{fCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3nRZRkUUN3ME2yMlMyOjN5IN88US=>MmHCV2FPT0WU
JVM-3NXjDeWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrlSZNEUUN3ME2yMlM1PjR|IN88US=>MVzTRW5ITVJ?
NCI-H2170NHXhUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILh[GRKSzVyPUKuN|Q4QDNizszNM4XPPXNCVkeHUh?=
EW-18NIjUV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HwVGlEPTB;Mj6zOVQ4OSEQvF2=M1LwVXNCVkeHUh?=
KU812M3GxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPRTWM2OD1{LkO2O|c6KM7:TR?=MnrDV2FPT0WU
NYMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTJwM{eyO{DPxE1?MnjJV2FPT0WU
HTC-C3NHLNNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnJTWM2OD1{LkSyNlY4KM7:TR?=NFjGWVdUSU6JRWK=
CFPAC-1NX3KemZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHtc|VCUUN3ME2yMlQ{QDZ2IN88US=>MkXMV2FPT0WU
HHNUDtOJZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTJwNEm4OVQh|ryPMXPTRW5ITVJ?
MKN7MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHDTWM2OD1{Lk[yO|Q5KM7:TR?=MVfTRW5ITVJ?
TE-8M3rnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXvfXlKSzVyPUKuOlM3PTNizszNNHe0UHRUSU6JRWK=
MC-IXCNIjCN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljVTWM2OD1{Lk[0OFU{KM7:TR?=MWXTRW5ITVJ?
DMS-79NHjTfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTJwNkmyPFQh|ryPMU\TRW5ITVJ?
Detroit562NFz1T|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvwV5lKSzVyPUKuOlk5PDVizszNMX3TRW5ITVJ?
HuP-T4NIi3S|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkW2TWM2OD1{LkeyPFE5KM7:TR?=MXnTRW5ITVJ?
QIMR-WILM3nCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3K3[mlEPTB;Mj63OVk2OiEQvF2=NHThV4FUSU6JRWK=
BB65-RCCNGXSXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7WTWM2OD1{LkiwO|E{KM7:TR?=MlnhV2FPT0WU
PC-3MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmn4TWM2OD1{LkizN|E4KM7:TR?=MVHTRW5ITVJ?
OVCAR-3NEHVNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTJwOEW1PVQh|ryPMl3zV2FPT0WU
KYSE-510NV;rPJV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33ud2lEPTB;Mj64Olc5PiEQvF2=Mk[wV2FPT0WU
HC-1NX30cHdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTJwOUSwNVIh|ryPNUO0NYR6W0GQR1XS
NCI-H1693M3myZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXuTWM2OD1{Lkm1PFk4KM7:TR?=Mlz0V2FPT0WU
DU-4475NGr5TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTJwOUmwOVIh|ryPM1LSSnNCVkeHUh?=
COLO-680NNFizNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\lTWM2OD1|LkCwOFk2KM7:TR?=NHzhTHRUSU6JRWK=
MN-60M3HRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTNwMES5O|Qh|ryPMUfTRW5ITVJ?
BCPAPNXLJemdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3e5OWlEPTB;Mz6wPFI6PSEQvF2=MVfTRW5ITVJ?
647-VNGCyXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTNwMU[yNkDPxE1?MU\TRW5ITVJ?
HT-1376NUHTSZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXDTWM2OD1|LkKwOVA3KM7:TR?=MUnTRW5ITVJ?
NCI-H1793M4fsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUe4ZZdpUUN3ME2zMlIyODl6IN88US=>NYPSWGRbW0GQR1XS
SW1463M1rTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\1TWM2OD1|LkK2NVkzKM7:TR?=NU[2flBVW0GQR1XS
NCI-H727MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nhV2lEPTB;Mz6zPFU5PCEQvF2=MUfTRW5ITVJ?
LB771-HNCMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFn4W41KSzVyPUOuN|kyOjZizszNM3PHbnNCVkeHUh?=
D-542MGMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPqV3R{UUN3ME2zMlQ1OjJ{IN88US=>NWXMUlNNW0GQR1XS
NTERA-S-cl-D1MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDrS2dKSzVyPUOuOFQ6PTdizszNMVvTRW5ITVJ?
C8166NV3tfWgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjMTWM2OD1|LkS2OVIyKM7:TR?=NXHWeFV[W0GQR1XS
639-VNUO2bGpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7sTWM2OD1|LkW3O|kzKM7:TR?=MmrrV2FPT0WU
TE-1NXSw[phjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTNwNUmxOlkh|ryPNWTYT2dVW0GQR1XS
OAW-28MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPDTWM2OD1|LkW5OFI3KM7:TR?=MWrTRW5ITVJ?
SK-LU-1NVSzeJRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF2xTItKSzVyPUOuOlA3PDVizszNM1fR[3NCVkeHUh?=
CaR-1NULwfZl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHMTWM2OD1|Lk[xNFQ5KM7:TR?=M2jKSHNCVkeHUh?=
A2780NHLaflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoC4TWM2OD1|Lk[0NFg6KM7:TR?=NInRWWlUSU6JRWK=
C2BBe1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HJcGlEPTB;Mz62OFQxPyEQvF2=M3KzXHNCVkeHUh?=
SK-MES-1NYrYTI1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTNwNkS2NVQh|ryPNFvHfpBUSU6JRWK=
PANC-10-05MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTNwN{KwO|Ih|ryPM1m4eHNCVkeHUh?=
J-RT3-T3-5NGHYSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTNwN{W0NFYh|ryPM4PPZnNCVkeHUh?=
ES4NYrq[GlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnhbpBKSzVyPUOuPFIzQDZizszNNIniNYlUSU6JRWK=
NCI-H28M3rpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXMXHJ5UUN3ME2zMlgzQTZzIN88US=>MVzTRW5ITVJ?
NCI-H1155M{fZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LXTmlEPTB;Mz64OFE2QSEQvF2=NF;0e5hUSU6JRWK=
KURAMOCHIM3nZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrFcotKSzVyPUOuPFYxPTZizszNMULTRW5ITVJ?
NCI-H69MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTNwOUCxO|gh|ryPNIPHSG9USU6JRWK=
IST-MES1NVPLXVhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjqNXpKSzVyPUOuPVQxOjlizszNNEnqdJNUSU6JRWK=
NH-12MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojqTWM2OD1|Lkm0NVg4KM7:TR?=NF7FWFZUSU6JRWK=
JVM-2NEjETmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVu0RVY4UUN3ME2zMlk1PzV{IN88US=>NFradpdUSU6JRWK=
EW-16NYO5dWlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml76TWM2OD1|Lkm1OVc4KM7:TR?=NFHrbIRUSU6JRWK=
NCI-H441NXnGfmVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjadnNbUUN3ME2zMlk4ODF2IN88US=>MVHTRW5ITVJ?
RCC10RGBMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUGwVlBkUUN3ME20MlAyOjR4IN88US=>NITVXG5USU6JRWK=
TCCSUPNU\ZXJg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvuTWM2OD12LkGxNFUh|ryPMUXTRW5ITVJ?
HL-60MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NESwV3BKSzVyPUSuNVIzPDFizszNNEmzOXNUSU6JRWK=
EW-11MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXDcoFKSzVyPUSuNVMzPjFizszNMUXTRW5ITVJ?
KARPAS-299M2nPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zGfmlEPTB;ND6zNVAyOyEQvF2=MnL0V2FPT0WU
SNU-C2BMlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rJSmlEPTB;ND6zOFY5PiEQvF2=MnfiV2FPT0WU
LU-139NEfp[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLLUXBKSzVyPUSuN|czPDdizszNM17SbXNCVkeHUh?=
HCC1937NH;PepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTRwM{e5PVMh|ryPMm\MV2FPT0WU
GR-STM3rjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTmXIJKSzVyPUSuOFMyQCEQvF2=M1yzSHNCVkeHUh?=
SK-OV-3MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnixTWM2OD12LkS2NFQzKM7:TR?=NV7YeWlsW0GQR1XS
A172NVzX[3RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoG0TWM2OD12LkW1OVIyKM7:TR?=MV\TRW5ITVJ?
NB10NUm3NHZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTRwNUm3PFEh|ryPM4fsXHNCVkeHUh?=
P30-OHKM1v5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3GwdGlEPTB;ND64NVkzQSEQvF2=M{fRR3NCVkeHUh?=
KYSE-520NH6wZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIqxc|hKSzVyPUSuPFgxOThizszNMYjTRW5ITVJ?
KNS-62NIXuZ|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEm5e2tKSzVyPUSuPVA5ODdizszNMXrTRW5ITVJ?
ES1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13QNGlEPTB;ND65OlA{PSEQvF2=MXjTRW5ITVJ?
KOSC-2NE\XcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF71THBKSzVyPUSuPVk6PTlizszNM{\nRnNCVkeHUh?=
TE-9M4DwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\zVJBVUUN3ME21MlAyPTJ3IN88US=>NWfnZW9yW0GQR1XS
NCI-H1838M2PzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGWxNWhKSzVyPUWuNFIxPzZizszNM{X1UHNCVkeHUh?=
KP-N-YNMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTVwMUK1PVEh|ryPMWHTRW5ITVJ?
ALL-POMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLzTWM2OD13LkKyOVg4KM7:TR?=MV3TRW5ITVJ?
NOMO-1NEWxPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTVwMkOxO|Yh|ryPM{TISHNCVkeHUh?=
CGTH-W-1M2\zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2L0S2lEPTB;NT6zPFU5PCEQvF2=NI\nfmhUSU6JRWK=
ATN-1NFroTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofJTWM2OD13LkSxNVg1KM7:TR?=M{jYc3NCVkeHUh?=
AGSNInxcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonTTWM2OD13LkS5OlE5KM7:TR?=MlvNV2FPT0WU
SW13NIPzb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofJTWM2OD13LkWzNlY2KM7:TR?=NHrKSVJUSU6JRWK=
SW1990NGDCZ|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PIdWlEPTB;NT62NlI5PSEQvF2=MXHTRW5ITVJ?
BFTC-905NEnocWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTVwNkW4O|gh|ryPMomwV2FPT0WU
RMG-IM{\FNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXENI8{UUN3ME21MlY2QTR{IN88US=>MmDaV2FPT0WU
HD-MY-ZNGDqR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrFTWM2OD13Lk[4OVgyKM7:TR?=NEj3TYlUSU6JRWK=
HCC1187NFizeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\JdmlEPTB;NT63NVA{OiEQvF2=NEG4bW9USU6JRWK=
HCC2998MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLwUWZKSzVyPUWuO|E5PzdizszNMoS4V2FPT0WU
RT-112NGLXTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzvTWM2OD13LkmwNlQ2KM7:TR?=MkfzV2FPT0WU
CAKI-1M2XHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1T2eWlEPTB;Nj6wNFk5PSEQvF2=MoX6V2FPT0WU
HDLM-2MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV73c4dGUUN3ME22MlAyPDh7IN88US=>MmOxV2FPT0WU
TE-10MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzxRpRoUUN3ME22MlA1QDN|IN88US=>NV:xOppqW0GQR1XS
KE-37MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHQTWM2OD14LkC3NlU5KM7:TR?=NGTiXnJUSU6JRWK=
RCM-1M4myUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWftPJh{UUN3ME22MlA4PzF7IN88US=>NXXybmJuW0GQR1XS
MewoMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkK1TWM2OD14LkGxOFg4KM7:TR?=MUfTRW5ITVJ?
L-428M1W0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTZXpN7UUN3ME22MlE5ODN5IN88US=>MVPTRW5ITVJ?
8-MG-BAMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfC[YpKSzVyPU[uNVk{PzlizszNMkDYV2FPT0WU
SK-MEL-28MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;wZmlEPTB;Nj6yNFk3PyEQvF2=NILTbFZUSU6JRWK=
VA-ES-BJM4rjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHpWG5KSzVyPU[uN|A1PjJizszNNVHxN5RXW0GQR1XS
CAL-120NUjldXpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fKXWlEPTB;Nj60OVE3OiEQvF2=M2rkZnNCVkeHUh?=
GAMGNIXkSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;BTWM2OD14LkWwOlIh|ryPM4P4[HNCVkeHUh?=
MSTO-221HM2\yWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfNeWNrUUN3ME22MlUyOTdizszNNGnzVVNUSU6JRWK=
GCTMnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PiPGlEPTB;Nj61N|M5PyEQvF2=MoCxV2FPT0WU
SH-4MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTTUo9KSzVyPU[uOVg5PDRizszNNV7ieJBVW0GQR1XS
Calu-3NW\Nc3JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\VbXFOUUN3ME22MlY2PTZ6IN88US=>M13mXnNCVkeHUh?=
SK-HEP-1MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\qS2lEPTB;Nj63NVc2OyEQvF2=MlH3V2FPT0WU
PFSK-1Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{iyNWlEPTB;Nj63N|Q4QCEQvF2=MVXTRW5ITVJ?
NB12NF\0[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{Xae2lEPTB;Nj63PFQxPCEQvF2=NITKdm5USU6JRWK=
A388NYS5ZohqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTnSVV5UUN3ME22Mlg6PTJizszNMYPTRW5ITVJ?
KLEMkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{L5dGlEPTB;Nj65OlUyPiEQvF2=NG[weXBUSU6JRWK=
TE-11NWPFOHRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTdwMES5Olch|ryPNYDwUGQ1W0GQR1XS
NCI-H2405MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPHcYRKSzVyPUeuNFg{QTNizszNM1q2dXNCVkeHUh?=
OVCAR-4MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTdwMUWzOUDPxE1?NUPwblBzW0GQR1XS
KP-N-YSMmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV31U4ozUUN3ME23MlE5OTRizszNMULTRW5ITVJ?
NOS-1M1m4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXSyS5FKUUN3ME23MlI2QDJ6IN88US=>M{PRVnNCVkeHUh?=
DMS-114M1\LV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{C0XGlEPTB;Nz6yPVY{OSEQvF2=MojzV2FPT0WU
NCI-H2030Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHLTWM2OD15LkOzOlk5KM7:TR?=MUnTRW5ITVJ?
HELMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LUUmlEPTB;Nz6zO|UzOSEQvF2=MorBV2FPT0WU
CAL-62NH;oS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXXPFZKSzVyPUeuN|k5PjZizszNNWnrS4xnW0GQR1XS
COLO-668MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjiRWdIUUN3ME23MlQ{QTZ5IN88US=>NG\wO4FUSU6JRWK=
SKG-IIIaMn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTdwNEWzPFEh|ryPNH;RSohUSU6JRWK=
HCC1419MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTdwNE[4N|Mh|ryPMUnTRW5ITVJ?
OS-RC-2MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF30OG9KSzVyPUeuOFk5QTRizszNM3LZWnNCVkeHUh?=
COLO-829NXfOcY1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;GcGlEPTB;Nz62OlQ3OyEQvF2=Mlq1V2FPT0WU
NB13MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\jTWM2OD15LkiyOlY4KM7:TR?=M3j0XXNCVkeHUh?=
DK-MGM4[2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3O4eWlEPTB;Nz64N|IxOSEQvF2=NGLrb3NUSU6JRWK=
SHP-77MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTdwOE[2OVMh|ryPNVXCbGRQW0GQR1XS
NCI-H661MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIe1bXBKSzVyPUiuNFU5PjdizszNNUnXT2o{W0GQR1XS
AM-38NUTGWnJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTvZ2w1UUN3ME24MlE3OjhizszNNXH5[pk6W0GQR1XS
VM-CUB-1NInLW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRThwMUewNlkh|ryPM1zvV3NCVkeHUh?=
KYSE-70MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRThwMUm3OlEh|ryPM3rISnNCVkeHUh?=
5637NGO1T|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PISWlEPTB;OD6zNVA2PSEQvF2=NFniZ5BUSU6JRWK=
TGBC11TKBNIf3TnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3G2ZmlEPTB;OD60OlE3PCEQvF2=MVvTRW5ITVJ?
EGI-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjr[2xzUUN3ME24MlYxODh6IN88US=>NGrCeJJUSU6JRWK=
D-392MGMm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnBTWM2OD16Lk[2NlE1KM7:TR?=MmfRV2FPT0WU
A673NVTQe3VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPC[HBGUUN3ME24MlY4PjFzIN88US=>M{TLZXNCVkeHUh?=
COLO-792MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfzPHZKSzVyPUiuO|Q6PDZizszNNXTzdJJ2W0GQR1XS
NCI-H1792MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPtTWM2OD16Lki4PVA{KM7:TR?=M{X6ZnNCVkeHUh?=
LS-1034M{\SRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRThwOUS2OVIh|ryPMU\TRW5ITVJ?
D-566MGNUDQTZNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LucGlEPTB;OT6wNVgyKM7:TR?=MnGxV2FPT0WU
NCI-H226MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M375OmlEPTB;OT6wPUDPxE1?MXXTRW5ITVJ?
ChaGo-K-1M32xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTlwMUC1O|kh|ryPMXrTRW5ITVJ?
NCI-H2228NVPS[mZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HKXGlEPTB;OT6xNVA5OSEQvF2=MV3TRW5ITVJ?
RPMI-8226NWLy[VhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2n6d2lEPTB;OT6xNVMxPCEQvF2=NXf1Z3J{W0GQR1XS
BFTC-909NFuyV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXxfWtKSzVyPUmuNVgzQTdizszNMmnWV2FPT0WU
HPAF-IINYDCW2RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTlwMkK1NVgh|ryPM{e5U3NCVkeHUh?=
Capan-2NWS0NmlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rrVWlEPTB;OT60NFExQSEQvF2=NXjTXopiW0GQR1XS
IA-LMMl7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnuRZBCUUN3ME25MlQyQTZ4IN88US=>MWnTRW5ITVJ?
KP-4NWfSblVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fPNWlEPTB;OT60PFg{QCEQvF2=NUjIPIQ1W0GQR1XS
A101DNYXWfXVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3rTWM2OD17LkWxO|E6KM7:TR?=MUHTRW5ITVJ?
EFO-21NIiy[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1uybmlEPTB;OT61PFc{PSEQvF2=MkLxV2FPT0WU
C32M4OzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFntWJJKSzVyPUmuOlM{PCEQvF2=M3\nUXNCVkeHUh?=
SW837Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\kXmpKSzVyPUmuPFQ5OiEQvF2=M4HXXXNCVkeHUh?=
OCI-AML2MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTlwOE[5OkDPxE1?MVzTRW5ITVJ?
NCI-H1355NXPEbnc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFuyZphKSzVyPUmuPVQxQDhizszNMnfYV2FPT0WU
NCI-H2342NXi3VIpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjITWM2OD1zMD6wNVU2KM7:TR?=MmnlV2FPT0WU
A204MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nHV2lEPTB;MUCuNFQ3PiEQvF2=MmfQV2FPT0WU
CAL-51Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY[zOZBbUUN3ME2xNE4xQDd5IN88US=>NWH1bI1bW0GQR1XS
HCE-4MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWC5OHhGUUN3ME2xNE4yOTJ{IN88US=>Mn31V2FPT0WU
NCI-H810NVTk[FNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTFyLkG1PVch|ryPM2[5N3NCVkeHUh?=
DJM-1NFzSfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\3TWM2OD1zMD6xO|MzKM7:TR?=NVK0PHB6W0GQR1XS
SK-UT-1NU\wco56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGKy[4ZKSzVyPUGwMlI2PzRizszNNIrEVYRUSU6JRWK=
U031NY\jOnc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPZTFBKSzVyPUGwMlI3QDZizszNM4nLc3NCVkeHUh?=
YH-13NUXnVGNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfR[WRKSzVyPUGwMlMxPTdizszNMljHV2FPT0WU
K5MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrBb3p7UUN3ME2xNE4{Ozl3IN88US=>M{P0d3NCVkeHUh?=
HEC-1M3PlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rkWGlEPTB;MUCuOFA5OSEQvF2=NG[ze5dUSU6JRWK=
A2058M13UVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLVflZ2UUN3ME2xNE42PDlzIN88US=>NEHZNnFUSU6JRWK=
SW962M{m1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTFyLk[yNFQh|ryPNH7E[25USU6JRWK=
VMRC-RCZNXS5fYN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fNUGlEPTB;MUCuOlc1QSEQvF2=NU\G[oJKW0GQR1XS
D-336MGNYTucZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXRTWM2OD1zMD63NFA2KM7:TR?=NXi1SJFIW0GQR1XS
LXF-289M3LncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HTZWlEPTB;MUCuO|k3PyEQvF2=MULTRW5ITVJ?
SW900NUTqTVMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Moe0TWM2OD1zMD64NlI5KM7:TR?=M4LFXHNCVkeHUh?=
K-562NITQXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGG3NG1KSzVyPUGwMlg{QTVizszNM3;YOHNCVkeHUh?=
HCC38NFzHWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIP5eJRKSzVyPUGwMlk4OTZizszNMX\TRW5ITVJ?
SF-295M4jWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPaNWpFUUN3ME2xNE46QTB{IN88US=>MnP3V2FPT0WU
LB831-BLCNU\yV21[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPBTWM2OD1zMT6yOVU3KM7:TR?=MYjTRW5ITVJ?
FTC-133MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\PZmlEPTB;MUGuN|A5OSEQvF2=M{jYXXNCVkeHUh?=
HCC1954M37IOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XXUmlEPTB;MUGuOFM3KM7:TR?=NYjxZopoW0GQR1XS
GOTONYjVS3NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzITWM2OD1zMT61NlA3KM7:TR?=MUHTRW5ITVJ?
LS-411NNV\tVodUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\PTWM2OD1zMT62NVAyKM7:TR?=NHHJeIZUSU6JRWK=
RPMI-7951MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXpTWM2OD1zMT62N|Q5KM7:TR?=MVfTRW5ITVJ?
NCI-H1299NVezZ4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlqyTWM2OD1zMT62OlQ4KM7:TR?=M1zCdXNCVkeHUh?=
MLMANE\EdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjqTWlKSzVyPUGxMlY6QTdizszNNIrGU5hUSU6JRWK=
MMAC-SFMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3P6cGlEPTB;MUGuO|I2OiEQvF2=NH;oUpVUSU6JRWK=
UM-UC-3MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHFcGV{UUN3ME2xNU44PDJzIN88US=>NX[4UlVRW0GQR1XS
SCC-9NHq0b3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYriV5BPUUN3ME2xNU45OTVzIN88US=>Mo\tV2FPT0WU
HOSMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTFzLki2PFMh|ryPMmXlV2FPT0WU
OE19MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTFzLkmzOlch|ryPMoW5V2FPT0WU
Mo-TNIPqV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\sXZpOUUN3ME2xNU46PTRzIN88US=>Ml7UV2FPT0WU
CAMA-1NX7JVYh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTF{LkG2N|Mh|ryPM4\jV3NCVkeHUh?=
U-118-MGM1nieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3n5SGlEPTB;MUKuNlQ1OSEQvF2=M2nJbHNCVkeHUh?=
KS-1NV:4NGNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGn1T|RKSzVyPUGyMlI5OzJizszNMkW4V2FPT0WU
JARNULXXXZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7zRWpOUUN3ME2xNk4{OzZ7IN88US=>M3TxUnNCVkeHUh?=
ABC-1NF\zO2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXPT5lKSzVyPUGyMlM1OSEQvF2=MVXTRW5ITVJ?
DaoyNXPnNFE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjlOW9KSzVyPUGyMlQ2PDJizszNMX\TRW5ITVJ?
C3AMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nN[mlEPTB;MUKuOVc5PSEQvF2=NFPPOJhUSU6JRWK=
GT3TKBMkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{naVmlEPTB;MUKuOlMzPyEQvF2=MV;TRW5ITVJ?
DMS-273MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXRNldoUUN3ME2xNk45PjN|IN88US=>NIn4cYtUSU6JRWK=
G-361NWjxbmdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLXTWM2OD1zMj65NVI6KM7:TR?=M3WxUXNCVkeHUh?=
RH-18MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzQc41KSzVyPUGzMlI6PjJizszNM2faOnNCVkeHUh?=
SN12CMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzaepdKSzVyPUGzMlM5ODhizszNNFrVcWpUSU6JRWK=
NCI-H1993M1Xxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTF|LkSyPFUh|ryPM2\CVnNCVkeHUh?=
LOXIMVIM4DFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDkTWM2OD1zMz62NVUyKM7:TR?=NEDvfI1USU6JRWK=
SK-PN-DWMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTF|Lki0Nlch|ryPMn;JV2FPT0WU
KALS-1NFru[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LEPGlEPTB;MUOuPFUzPSEQvF2=M2HkS3NCVkeHUh?=
LAN-6Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTF2LkK1N{DPxE1?NFqzWW9USU6JRWK=
A549Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTF2LkS3NVIh|ryPMojSV2FPT0WU
RDMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLpTphKSzVyPUG0MlQ5OTNizszNM4fpdHNCVkeHUh?=
TGBC1TKBM1u2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXpVlZKSzVyPUG0MlY3OTVizszNMmPPV2FPT0WU
NCI-H630MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTF2Lkm0Olch|ryPMl65V2FPT0WU
MIA-PaCa-2NFrQOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\mTWM2OD1zND65Olkh|ryPNUPtcHN3W0GQR1XS
NCI-H1755NU\ERZpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fsXGlEPTB;MUSuPVk2OyEQvF2=NX7TXmV2W0GQR1XS
MOLT-4NEH4SnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{nTWmlEPTB;MUWuNFQ6PyEQvF2=M1n4bXNCVkeHUh?=
CW-2MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV32VGhPUUN3ME2xOU4yPDJzIN88US=>NX3pVFZvW0GQR1XS
COLO-320-HSRNIezT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfabGlKSzVyPUG1MlU{ODdizszNMXTTRW5ITVJ?
UMC-11MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXpRWtLUUN3ME2xOU44PTJ|IN88US=>NH3JUXlUSU6JRWK=
MCF7M{XTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTF3LkixOFUh|ryPMUnTRW5ITVJ?
NCI-H23Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXyzfVhqUUN3ME2xOU45PDN6IN88US=>NWjmWYcxW0GQR1XS
HuCCT1NX\afI1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLYTWM2OD1zNT64O|Qh|ryPM2jMd3NCVkeHUh?=
MPP-89NXjFeZNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XGWWlEPTB;MUWuPVQyPyEQvF2=M{HJPHNCVkeHUh?=
HT55NUT3RZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDJSZJKSzVyPUG1Mlk1PzhizszNMV3TRW5ITVJ?
no-11M4XEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmS5TWM2OD1zNT65OlY{KM7:TR?=M2H4[HNCVkeHUh?=
GP5dM37l[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPGRYVLUUN3ME2xOk4zOTh5IN88US=>MV;TRW5ITVJ?
BHT-101NWDXc5BGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHVc2lKSzVyPUG2MlI1OzlizszNM4TLdHNCVkeHUh?=
M059JM4PZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLJZmZKSzVyPUG2MlI5PCEQvF2=NFLwRotUSU6JRWK=
D-283MEDNV3Oe5oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;sTWM2OD1zNj60NlA6KM7:TR?=NYfCXoNWW0GQR1XS
BENM3HDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3MTWM2OD1zNj61NVU2KM7:TR?=NVzHcXNZW0GQR1XS
LB373-MEL-DNV;HSZhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFiwdY9KSzVyPUG2MlczOzJizszNNFi5Z3lUSU6JRWK=
MEL-HONVK1TJB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkS2TWM2OD1zNj64PFU1KM7:TR?=NWXm[m9WW0GQR1XS
GI-ME-NNX\hZYZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTF4LkmwN|Ih|ryPNGLNVplUSU6JRWK=
RKOMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPKTWM2OD1zNz6wO|Q5KM7:TR?=NX6yZXl1W0GQR1XS
MZ2-MELNVP0WFYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XFU2lEPTB;MUeuNVM{KM7:TR?=NFizVI5USU6JRWK=
NCI-H1573NXnMXGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Lje2lEPTB;MUeuNlgzPiEQvF2=M3\DbXNCVkeHUh?=
NCI-H1581M3fkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XkfmlEPTB;MUeuOFQyOSEQvF2=MYDTRW5ITVJ?
NCI-H747M{H4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nWN2lEPTB;MUeuOVI6PyEQvF2=M4TsSnNCVkeHUh?=
SW1783M1XJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEf4dZBKSzVyPUG3MlY1OTVizszNMXrTRW5ITVJ?
Calu-6MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1T2OWlEPTB;MUeuOlc5OiEQvF2=MnjiV2FPT0WU
SF268NWezV2tET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvGZndPUUN3ME2xO{43QTZ7IN88US=>M3raSHNCVkeHUh?=
ES8NG\UeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfnTWM2OD1zNz64OVk{KM7:TR?=NYDISld5W0GQR1XS
KM-H2MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVO5R4pKUUN3ME2xO{46PDFzIN88US=>Ml;iV2FPT0WU
D-502MGNXfBfYhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvhd4pYUUN3ME2xO{46QDB6IN88US=>M2LUbHNCVkeHUh?=
HLENFPROFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\vXYhKSzVyPUG4MlMyPDhizszNMYHTRW5ITVJ?
SW982NFzYPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXi5XZJ{UUN3ME2xPE41ODd3IN88US=>NGLkNlVUSU6JRWK=
MDA-MB-361NYDxXlZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37k[2lEPTB;MUiuOVU5QCEQvF2=NYrjWll2W0GQR1XS
NCI-H1563NXTHVlB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnW4TWM2OD1zOD63NVI1KM7:TR?=MUPTRW5ITVJ?
MFE-280M1P6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M322eWlEPTB;MUiuO|I6OyEQvF2=NGHONolUSU6JRWK=
U251MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTF6LkezOFch|ryPNHjnc4VUSU6JRWK=
KNS-42NUO2bHI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlj0TWM2OD1zOD64NFE2KM7:TR?=NIe2NnZUSU6JRWK=
U-266M{PFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrITWM2OD1zOD64OlQ6KM7:TR?=NF7WbFFUSU6JRWK=
OVCAR-8NV3uRW9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LLNWlEPTB;MUiuPVI4PiEQvF2=MXXTRW5ITVJ?
MFH-inoMkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHf6dXJKSzVyPUG4Mlk3PjlizszNM4LXNHNCVkeHUh?=
D-263MGMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTF7LkCxO|Ih|ryPNHjh[5dUSU6JRWK=
NCI-H1437MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnX5TWM2OD1zOT6wOFY4KM7:TR?=NWLLOFlSW0GQR1XS
NCI-H1048MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXheHNKSzVyPUG5MlI{OjZizszNMkf0V2FPT0WU
NCI-H446NUHq[YRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XSfmlEPTB;MUmuN|U5QSEQvF2=MnPqV2FPT0WU
NCI-N87MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3BTWM2OD1zOT61PVkzKM7:TR?=NEPHdlBUSU6JRWK=
WM-115Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWn0fmVzUUN3ME2xPU43Pzd2IN88US=>MVrTRW5ITVJ?
HuH-7NV2xZWNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXkTI12UUN3ME2xPU44PDJzIN88US=>M{PUTHNCVkeHUh?=
NCI-H650MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTF7Lke1NFgh|ryPMYXTRW5ITVJ?
TYK-nuM1j3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn:3TWM2OD1zOT64N|c5KM7:TR?=NVrSU3JpW0GQR1XS
BeckerMk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXt[W8{UUN3ME2xPU45PTR5IN88US=>MX7TRW5ITVJ?
BB49-HNCM2HHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofCTWM2OD1zOT65NkDPxE1?MnfjV2FPT0WU
HGC-27NH;FNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFyyfIVKSzVyPUKwMlE{QTRizszNMkXDV2FPT0WU
SiHaNVywUINRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfGbYRwUUN3ME2yNE4{PzF{IN88US=>M4\RU3NCVkeHUh?=
LB2518-MELMnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\yVXBKSzVyPUKwMlM4OzlizszNM2X6[nNCVkeHUh?=
TE-5NYrZNmdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTJyLke0PFIh|ryPMXfTRW5ITVJ?
IST-SL1NYTYZZRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETSb|dKSzVyPUKwMlc5PzlizszNNX7CbopvW0GQR1XS
A375MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTJzLkC1Olch|ryPMmSxV2FPT0WU
MC116M3;idGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnqxTWM2OD1{MT6wO|I{KM7:TR?=NXfWfHpqW0GQR1XS
GI-1NXr3b4puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTDZZh1UUN3ME2yNU4yPyEQvF2=MmnvV2FPT0WU
HOP-62NELzfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTJbW1[UUN3ME2yNU4zPzh2IN88US=>NEXrT|ZUSU6JRWK=
PA-1M2PSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHMdHRKSzVyPUKxMlI4QDdizszNMnLFV2FPT0WU
HTMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoT2TWM2OD1{MT60N|MyKM7:TR?=M4PZZnNCVkeHUh?=
HUTU-80MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTJzLkSzN|Yh|ryPMmPyV2FPT0WU
NCI-H1975NXm2SZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFz0b49KSzVyPUKxMlQ3OSEQvF2=MoO0V2FPT0WU
GAKM{O2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XSeWlEPTB;MkGuOFk6KM7:TR?=M3PTZnNCVkeHUh?=
SK-N-ASM3HTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTJzLkW2NVkh|ryPMV\TRW5ITVJ?
OE33MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDYNGhQUUN3ME2yNU43ODR4IN88US=>NFXuNVhUSU6JRWK=
YKG-1M2X5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnMTWM2OD1{MT62OVQ2KM7:TR?=MnnBV2FPT0WU
CAL-85MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHQcJBKSzVyPUKxMlk{ODVizszNNYG5bGdHW0GQR1XS
NCI-H2347MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDNTWM2OD1{MT65OFI5KM7:TR?=M4TOfXNCVkeHUh?=
PANC-08-13NWn1UlVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjQSXJKSzVyPUKyMlAyOTlizszNNHG0RopUSU6JRWK=
SK-N-FINIi5XmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXeyOXp4UUN3ME2yNk4{ODd2IN88US=>MnjzV2FPT0WU
NEC8NE\tVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTJ{LkWwO|gh|ryPM{DvPHNCVkeHUh?=
AN3-CAMnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTJ{Lk[wPFQh|ryPMUjTRW5ITVJ?
HuO9Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;TWWlEPTB;MkKuO|M6PiEQvF2=NGfCNm5USU6JRWK=
COLO-800MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXCdWNyUUN3ME2yNk44PjV|IN88US=>NYHJXFZNW0GQR1XS
HT-29MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{e3OWlEPTB;MkKuPFgzOyEQvF2=MmXYV2FPT0WU
OC-314MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlruTWM2OD1{Mj64PFQ2KM7:TR?=M4fFUXNCVkeHUh?=
G-401NITRb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPuTWM2OD1{Mz6wOFYzKM7:TR?=NXjQUYRuW0GQR1XS
Saos-2M3LwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfFZ4VXUUN3ME2yN{42OTh{IN88US=>MnPmV2FPT0WU
UACC-62M17FPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2q1W2lEPTB;MkOuOVg{OyEQvF2=NGnibFBUSU6JRWK=
D-247MGM4S5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NID5[IpKSzVyPUKzMlc6OzlizszNNXH1bWp6W0GQR1XS
COLO-741NV34PIZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmL4TWM2OD1{Mz65OVY2KM7:TR?=Mn\0V2FPT0WU
ES3NFjXPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXlb21wUUN3ME2yOE4xODJ|IN88US=>MU\TRW5ITVJ?
LNCaP-Clone-FGCMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnN[mt4UUN3ME2yOE4xOjFzIN88US=>NILhWo9USU6JRWK=
SW1710M3jU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGric4tKSzVyPUK0MlE2ODZizszNMor1V2FPT0WU
LU-99AMmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoiwTWM2OD1{ND6xPFQyKM7:TR?=MoflV2FPT0WU
HOP-92MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fWVmlEPTB;MkSuO|I2KM7:TR?=NGDKZ|JUSU6JRWK=
LS-123NHi5T5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEH5S5JKSzVyPUK0Mlk3OTRizszNMmLQV2FPT0WU
T84NFrUV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLsUotKSzVyPUK0Mlk4PjVizszNNVyyUnZnW0GQR1XS
HCT-116MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M336SGlEPTB;MkWuOFE5PiEQvF2=Mk\NV2FPT0WU
M14NULKbVdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjWNGpoUUN3ME2yOU41PDR5IN88US=>Mo\LV2FPT0WU
OCUB-MNY\J[FlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\JZWp3UUN3ME2yOU41PDV4IN88US=>MonWV2FPT0WU
MKN45NH\ScZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVG5R4JpUUN3ME2yOU43OzF3IN88US=>MXrTRW5ITVJ?
LCLC-97TM1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTTOFFKUUN3ME2yOU44Ojh3IN88US=>M16xcnNCVkeHUh?=
RVH-421NFzkd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjHTWM2OD1{NT64NVYyKM7:TR?=MX7TRW5ITVJ?
NKS-81-FDM{L1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPkbWJGUUN3ME2yOU46ODJzIN88US=>NVywXWw6W0GQR1XS
NCI-H596M1TEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGL3OJlKSzVyPUK2MlA1QDdizszNMl20V2FPT0WU
GB-1NFywNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjZVVZbUUN3ME2yOk4yQDd7IN88US=>NISwOoxUSU6JRWK=
ZR-75-30MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;KPVdKSzVyPUK2MlIzQTdizszNM2f5fHNCVkeHUh?=
U-2-OSMlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPQXIdKSzVyPUK2MlM4PTdizszNMkLLV2FPT0WU
HuP-T3M1Hjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nNPWlEPTB;Mk[uOlExOiEQvF2=NGq3XFFUSU6JRWK=
MOLT-16NFXpeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXH5dnpmUUN3ME2yOk43OTZ4IN88US=>NEjWdXlUSU6JRWK=
U-87-MGM2LkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjaTWM2OD1{Nj63OFM5KM7:TR?=NVTKTFVLW0GQR1XS
8505CMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTrflVyUUN3ME2yOk46OTJ4IN88US=>NFv3[mlUSU6JRWK=
SK-MEL-3MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTJ4Lkm4Nlgh|ryPM{exd3NCVkeHUh?=
COLO-824Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfVWZU6UUN3ME2yO{4zOTl3IN88US=>M2fOenNCVkeHUh?=
EW-1M4[2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLWOJRKSzVyPUK3MlM2PTRizszNNWjHUHhkW0GQR1XS
UACC-257NInjPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fNVmlEPTB;MkeuN|gxPCEQvF2=NWexOIJRW0GQR1XS
Hs-578-TNF7U[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjabYxKSzVyPUK3MlUzQTlizszNNFvjZWxUSU6JRWK=
UACC-893MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXOW5FKSzVyPUK3MlY3OzFizszNNF7HS|dUSU6JRWK=
MHH-NB-11M3XWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDKW45KSzVyPUK3MlgxODdizszNNVLPO45qW0GQR1XS
KYSE-410NUexPGE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTJ6LkK3O|kh|ryPMXPTRW5ITVJ?
SF126NG\YXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fCbGlEPTB;MkiuO|Q{PSEQvF2=M2rpOHNCVkeHUh?=
HT-144NGXzW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTJ7LkOzOlIh|ryPMV\TRW5ITVJ?
SW1573NGG1dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLWTWM2OD1{OT6zOVA6KM7:TR?=MUnTRW5ITVJ?
SW620Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vTUGlEPTB;MkmuN|Y1OSEQvF2=NVy0Zmc4W0GQR1XS
SCHM1rROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTJ7Lki4N|Eh|ryPNGH6[WlUSU6JRWK=
EW-22NE\NeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3kWI9YUUN3ME2zNE4yQTZ7IN88US=>MXnTRW5ITVJ?
H4NH7xdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3j4eGlEPTB;M{CuOFY2PCEQvF2=NH35fIZUSU6JRWK=
CAS-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLFTWM2OD1|MD63PFU6KM7:TR?=NXzHZ|NPW0GQR1XS
MG-63NFP6dnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTNyLki0O|gh|ryPMYDTRW5ITVJ?
MDA-MB-415NIH3S2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTNzLkG3OVMh|ryPNYP1N2FnW0GQR1XS
NCI-H1395M1yxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXCZY9KSzVyPUOxMlI{OjhizszNM1PCW3NCVkeHUh?=
Ca-SkiMl3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfQWHR5UUN3ME2zNU4{OTd5IN88US=>NIjTT2ZUSU6JRWK=
BxPC-3M3;FXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;TTWM2OD1|MT6zO|I6KM7:TR?=NI[5RmdUSU6JRWK=
A3-KAWNGjXe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\GTWM2OD1|MT60OFcyKM7:TR?=MXTTRW5ITVJ?
T-24MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXUcVJKSzVyPUOxMlc{PjJizszNNYXwV3hjW0GQR1XS
NCI-H2029NEL5bVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPuc3lKSzVyPUOxMlc4PjVizszNNFrTSotUSU6JRWK=
YAPCM12w[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGn3cFVKSzVyPUOyMlA1ODdizszNNXTzOXZiW0GQR1XS
SK-MEL-2NXHsVXdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fHXmlEPTB;M{KuNFUzKM7:TR?=MlXSV2FPT0WU
LS-513MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvKSnBWUUN3ME2zNk4yOTh5IN88US=>NWewSHI5W0GQR1XS
AsPC-1NEntXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTN{LkO2NFUh|ryPMmXGV2FPT0WU
KYSE-150M4\kNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzQcWs{UUN3ME2zNk4{Pzd|IN88US=>M1\TNHNCVkeHUh?=
NCI-H520Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnQTWM2OD1|Mj60OFgzKM7:TR?=MWDTRW5ITVJ?
JEG-3MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTzTWM2OD1|Mz6wPVcyKM7:TR?=MoPiV2FPT0WU
GMS-10M3HEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrTN3VKSzVyPUOzMlMxODRizszNNHm5RodUSU6JRWK=
HT-1080NGrNUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\CboRKSzVyPUOzMlM6KM7:TR?=MYrTRW5ITVJ?
NCI-H1651MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUW3Oow4UUN3ME2zN{4{QTZizszNM2HVNHNCVkeHUh?=
NCI-H2122MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTN|LkW1O|Qh|ryPM121RXNCVkeHUh?=
ES5M{\LOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTvTWM2OD1|Mz63NlkzKM7:TR?=MW\TRW5ITVJ?
8305CM3vwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHr0U3dKSzVyPUOzMlk6OzdizszNMn7TV2FPT0WU
KM12NVfSfJZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTN2LkC0O|gh|ryPMofCV2FPT0WU
HCT-15NVfSWWtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13nOWlEPTB;M{SuNVI4KM7:TR?=NIHwS41USU6JRWK=
OVCAR-5NXjJe4NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnz5TWM2OD1|ND6yNVgzKM7:TR?=M{X4VXNCVkeHUh?=
NCI-H2291NGDP[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3ewSGlEPTB;M{SuNlQ4OiEQvF2=MkTkV2FPT0WU
CP50-MEL-BNX7CVoRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTN2Lk[1PVIh|ryPNUW0VWJLW0GQR1XS
C-33-AMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HSOmlEPTB;M{SuOlg2PyEQvF2=MWXTRW5ITVJ?
NCI-H2452NXLBWXgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHGTWM2OD1|ND63PFgzKM7:TR?=M2TERXNCVkeHUh?=
MDA-MB-157M2fze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnsS|FKSzVyPUO0MlgyQTNizszNNYLBdIJ5W0GQR1XS
LN-405MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\BOWxKSzVyPUO1MlQ{ODhizszNMkHkV2FPT0WU
MDA-MB-231M4XBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHXOVRUUUN3ME2zOU42ODV2IN88US=>MlTkV2FPT0WU
EW-24MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3qxemlEPTB;M{WuOlM{PSEQvF2=M1yyRnNCVkeHUh?=
MKN28NWHvUVNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fi[WlEPTB;M{WuPFI{PiEQvF2=MVPTRW5ITVJ?
KINGS-1NHjGe2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;2dWtFUUN3ME2zOU45PDN2IN88US=>NHy4VYZUSU6JRWK=
LC-2-adNYW1fmpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LwW2lEPTB;M{[uOlk6KM7:TR?=MmO3V2FPT0WU
IGR-1NILzcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrH[mtOUUN3ME2zOk44ODd3IN88US=>NGHEcFBUSU6JRWK=
SW626MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PzVmlEPTB;M{euNFQyPyEQvF2=MnnmV2FPT0WU
ONS-76MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLpTWM2OD1|Nz6xN|A6KM7:TR?=MVjTRW5ITVJ?
T98GMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4P4e2lEPTB;M{euPFY{PSEQvF2=NXHaUlFIW0GQR1XS
NB14NXu2THZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\MeFVKSzVyPUO4MlQ2PDRizszNM3PoOnNCVkeHUh?=
D-423MGNXnSOYFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{KzbGlEPTB;M{iuOFg3QSEQvF2=MXzTRW5ITVJ?
NCI-H510AMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3NNItKSzVyPUO4MlY1PTFizszNNUjufGNVW0GQR1XS
NMC-G1NF3ZeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTN6LkeyNlIh|ryPMYHTRW5ITVJ?
SW948MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPMTWM2OD1|OD64PVQ6KM7:TR?=M4TufXNCVkeHUh?=
MFM-223MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmq4TWM2OD1|OD65OFMyKM7:TR?=MVzTRW5ITVJ?
PAN1MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTN6Lkm5NVkh|ryPNXjmTJRQW0GQR1XS
MZ7-melMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLJTWM2OD1|OT6xNVk6KM7:TR?=MlPuV2FPT0WU
COLO-679NUH1eXJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLxSFNKSzVyPUO5Mlk4ODhizszNMkHKV2FPT0WU
SW872NELnTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4G2d2lEPTB;NECuNlA{OSEQvF2=MX7TRW5ITVJ?
HT-1197MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrQTYo4UUN3ME20NE4zQDZ7IN88US=>MlXYV2FPT0WU
ES6NITheJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TVW2lEPTB;NECuOFU2OiEQvF2=M1PXZnNCVkeHUh?=
SNU-387NEi3[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTRyLkiyN|gh|ryPMnTrV2FPT0WU
T47DNVvYWIUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\yWFkzUUN3ME20NU4xOTl{IN88US=>MVTTRW5ITVJ?
G-402NILJS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTRzLkC4NFkh|ryPNUPuUIY1W0GQR1XS
MZ1-PCMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIeyRmhKSzVyPUSxMlgyKM7:TR?=MWfTRW5ITVJ?
SW1417Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEmycWJKSzVyPUSyMlMxOyEQvF2=MV3TRW5ITVJ?
RERF-LC-MSMlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTR{LkWwPFch|ryPNITmNGlUSU6JRWK=
SF539NUPTclZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrFTHVKSzVyPUSyMlU2OjlizszNNHLZfWxUSU6JRWK=
ESS-1MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjQOWhKSzVyPUSzMlU2PThizszNMoKzV2FPT0WU
RO82-W-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLVTWM2OD12Mz62NVU{KM7:TR?=NFvBTZRUSU6JRWK=
S-117NUDqem5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjRfIJUUUN3ME20N{43QTV6IN88US=>M2rkUnNCVkeHUh?=
SW756M3i5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknzTWM2OD12Mz64NlQzKM7:TR?=NWqxeHRZW0GQR1XS
CP66-MELM4rrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\qOGlEPTB;NEWuO|E1OyEQvF2=NIntRnVUSU6JRWK=
H-EMC-SSMkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7TTWM2OD12NT63Olk{KM7:TR?=M{OwXXNCVkeHUh?=
NCI-H2052NFyxelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlP0TWM2OD12NT65NFI4KM7:TR?=M1\oVHNCVkeHUh?=
SW684M363NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;2SHN5UUN3ME20O{4xODhzIN88US=>NIG5XG5USU6JRWK=
HCC1569M3r4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rN[GlEPTB;NEeuNVY2QCEQvF2=NXvEcWZKW0GQR1XS
KGNMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nRU2lEPTB;NEeuN|MyOSEQvF2=NYX3e41rW0GQR1XS
LCLC-103HNF;mWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUn2NFRJUUN3ME20O{41PDB2IN88US=>M1r6RnNCVkeHUh?=
SW780NUHwb3RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHEXJlPUUN3ME20O{43OzVzIN88US=>NITEU4dUSU6JRWK=
NCI-H1703M{n0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHVXJJMUUN3ME20PE4{OzV{IN88US=>M4C2XnNCVkeHUh?=
HCC1395Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYL1fnUyUUN3ME20PE44PDN{IN88US=>MknIV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. [3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. [4]
Features A potent EGFR tyrosine kinase inhibitor.

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines NR6, NR6M and NR6W cells
Concentrations 0-2 μM
Incubation Time 72 hours
Method Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.

Animal Study: [3]

Animal Models Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation 0.5% polysorbate
Dosages 100 mg/kg
Administration Once daily by oral administration (0.1 mL/10 g body weight) for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Pedersen MW, et al. Br J Cancer. 2005, 93(8), 915-923.

[2] Moasser MM, et al. Cancer Res. 2001, 61(19), 7184-7188.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-04-16)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02740894 Completed Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ? Taipei Veterans General Hospital, Taiwan February 2016 --
NCT02347839 Recruiting Lung Cancer Sun Yat-sen University January 2016 Phase 2
NCT02588261 Recruiting Non-small Cell Lung Cancer (NSCLC) Astellas Pharma Global Development, Inc.|Astellas Pharma Inc November 2015 Phase 3
NCT02326285 Recruiting Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage I  ...more Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage IIIB|Activating EGFR Mutation|NSCLC AIO-Studien-gGmbH|AstraZeneca November 2015 Phase 2|Phase 3
NCT02321293 Recruiting Lung Cancer Lady Davis Institute|Jewish General Hospital August 2015 Phase 1

view more

Chemical Information

Download Gefitinib (ZD1839) SDF
Molecular Weight (MW) 446.90
Formula

C22H24ClFN4O3

CAS No. 184475-35-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 89 mg/mL (199.14 mM)
Ethanol 4 mg/mL (8.95 mM)
Water <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose/0.2% Tween 80 12 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine

Customer Product Validation (11)


Click to enlarge
Rating
Source Mol Syst Biol 2011 7, 486. Gefitinib (ZD1839) purchased from Selleck
Method qPCR analysis
Cell Lines glioblastoma cell lines
Concentrations 5 μM, 50 ng/ml
Incubation Time 6 h
Results We perturbed the activity of the EGFR by activating it using one of its ligands (EGF) and inhibiting it with a selective EGFR inhibitor (Gefitinib). As readout, we measured the transcriptional effect on SOCS2 (a modulator of STAT signaling), NR2E1(also known as TLX , a transcription factor believed to be important for neural stem cell renewal), yielding results compatible with a coupling between hub perturbation and transcriptional response.

Click to enlarge
Rating
Source Oncogene 2010 30, 737-750. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines MEFs
Concentrations 1 μM
Incubation Time 48 h
Results We found that gefitinib, a specific EGFR inhibitor, almost completely recapitulated the results obtained by genistein (Figure a). Consistent with these results, we observed increased EGFR phosphorylation within 2 days of RECK depletion , with insignificant change in its protein amount (Figure b).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955 . Gefitinib (ZD1839) purchased from Selleck
Method Luciferase assay
Cell Lines LNCaP-AI cells, LNCaP cells
Concentrations 20 μM
Incubation Time 24 h
Results EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas Gefitinib and other inhibitors all tested downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells)

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Gefitinib (ZD1839) purchased from Selleck
Method ELISA
Cell Lines LNCaP-AI cells
Concentrations 20 μM
Incubation Time 24 h
Results Lapatinib, LY294002 and Bortezomib significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells .

Click to enlarge
Rating
Source J Immunother 2011 34(4), 372-81. Gefitinib (ZD1839) purchased from Selleck
Method Cytotoxicity assay
Cell Lines NK-92 cells/ lung cancer cells
Concentrations 10 μM
Incubation Time 24 h
Results Susceptibility of lung cancer cells to cytolytic activity of NK cells was significantly increased by treatment with EGFR inhibitors (erlotinib/gefitinib) and was reversed by blocking step using mAb against NKG2D before the assay in all lung cancer cells.

Click to enlarge
Rating
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Proliferation assay, Plaque reduction test, Western blot, Real-time PCR
Cell Lines Hep2 cells
Concentrations 0.01-1000 μM
Incubation Time
Results While for Gefitinib concentrations between 100 μM and 0.01 μM the proliferation rate was almost 100% of the controls, only at concentrations of 1000 μM a slight (24%) decline in proliferation was observed (Fig.A). IC50 values of Gefitinib for plaque size reduction were calculated by dividing plaque size by total size of one tissue culture plate well for each compound concentration. A non-linear regression fit curve analysis from the calculated values revealed for plaque size reduction an IC50 value of 4.93μM for Gefitinib(Fig. B).The analysis of phosphorylated EGFR and of the downstream signaling kinases ERK1/2 in cell lysates of the assay confirmed the dose dependency of the antiviral effect of Gefitinib. Kinase activ-ities were completely suppressed at concentrations above 1μM as determined by Western blot analysis. VACV proteins were not detectable between 10 μM and 100 μM in Western blot analysis anymore (Fig. C).

Click to enlarge
Rating
Source Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck
Method Immunofluorescence
Cell Lines Hep2 cells
Concentrations 0.01-1000 nM
Incubation Time 96 h
Results As shown in Fig. A, an immunofluorescent staining of a plaque reduction test was performed 96 h after viral infection. VACV infected cells were treated with 1000 μM, 1 μM or 0.01 μM Gefitinib and compared to uninfected cells after 96 h incubation. At concentrations of 1000 μM Gefitinib virus induced plaques were rarely found in cell culture and infected cells only could be identified by fluorescent staining of orthopoxvirus proteins (green) but not by light microscopy. At this Gefitinib concentration EGFR phosphorylation was completely suppressed in the cells and even the uninfected, untreated control cells show a stronger pEGFR signal (control, red). Occasionally found plaques, visible by flourescence microscopy only, showed a very compact shape with minimal disruption in its center. At the lower Gefitinib concentrations plaques showed an increasing number of infected and pEGFR positive cells (merge, yellow) and a surround-ing small zone of solely pEGFR positive cells (red). The lower the Gefitinib concentration the more plaques with a disrupted center were observed (1μM and 0.01μM). Most of the cells localized in the center of the plaque were positive for orthopoxvirus infection but negative for pEGFR ( Fig. B).

Click to enlarge
Rating
Source Mol Biosyst 2011 7, 3223-33. Gefitinib (ZD1839) purchased from Selleck
Method Immunoprecipitation/Western blotting
Cell Lines
Concentrations 5 μM
Incubation Time 0-1 h
Results In the presence of the EGFR tyrosine kinase inhibitor Z D1839 (Iressa) revealed that the observed increase in binding between PCM1 and Azi1 is specific to EGFs timulation and requires E GFR activation.

Click to enlarge
Rating
Source Int J Proteomics 2011 215496. Gefitinib (ZD1839) purchased from Selleck
Method CEER assay
Cell Lines H358 cell line
Concentrations 0.01-10 μM
Incubation Time 4 h
Results HER1 and/or HER2 pathway-activated cell lines, H358 , had their activation blocked by the HER1/2 kinase inhibitors Gefitinib.

Click to enlarge
Rating
Source 2010 Dr. Zhang of Tianjin Medical University. Gefitinib (ZD1839) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-5 nM
Incubation Time 24 h
Results

Click to enlarge
Rating
Source 2010 Dr. Vicky Tin from University of Hong Kong. Gefitinib (ZD1839) purchased from Selleck
Method MTT assay
Cell Lines H1299 cells, H358 cells, H25 cells, HCC827 cells
Concentrations 0-400 nM
Incubation Time 72 h
Results

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992)

    Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Gefitinib (ZD1839) | Gefitinib (ZD1839) ic50 | Gefitinib (ZD1839) price | Gefitinib (ZD1839) cost | Gefitinib (ZD1839) solubility dmso | Gefitinib (ZD1839) purchase | Gefitinib (ZD1839) manufacturer | Gefitinib (ZD1839) research buy | Gefitinib (ZD1839) order | Gefitinib (ZD1839) mouse | Gefitinib (ZD1839) chemical structure | Gefitinib (ZD1839) mw | Gefitinib (ZD1839) molecular weight | Gefitinib (ZD1839) datasheet | Gefitinib (ZD1839) supplier | Gefitinib (ZD1839) in vitro | Gefitinib (ZD1839) cell line | Gefitinib (ZD1839) concentration | Gefitinib (ZD1839) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us